Tuberculosis as A Metaphor for Isolation: An Interdisciplinary Examination of Tuberculosis by Pavlick, Stefanie
DePauw University
Scholarly and Creative Work from DePauw University
Student research Student Work
2015
Tuberculosis as A Metaphor for Isolation: An
Interdisciplinary Examination of Tuberculosis
Stefanie Pavlick
DePauw University
Follow this and additional works at: http://scholarship.depauw.edu/studentresearch
Part of the Bacterial Infections and Mycoses Commons, and the Therapeutics Commons
This Thesis is brought to you for free and open access by the Student Work at Scholarly and Creative Work from DePauw University. It has been
accepted for inclusion in Student research by an authorized administrator of Scholarly and Creative Work from DePauw University. For more
information, please contact bcox@depauw.edu.
Recommended Citation
Pavlick, Stefanie, "Tuberculosis as A Metaphor for Isolation: An Interdisciplinary Examination of Tuberculosis" (2015). Student
research. Paper 33.
	   
Tuberculosis as A Metaphor for Isolation:  
 
An Interdisciplinary Examination of Tuberculosis 
 
 
 
 
 
 
 
 
 
Stefanie Pavlick, 2015 
 
Sponsor: Dr. Pascal Lafontant 
 
Committee: Dr. Sharon Crary, Dr. Rebecca Upton, and Dr. Marnie McInnes 
 	  
 
	  Table of Contents          
    
Acknowledgements………………………………………………………………………………1 
 
Preface……………………………………………………………………………………….........3 
 Prelude…………………………………………………………………………………...10 
 
Background…………………………………………………………………………………......11 
 History……………………………………………………………………………………11 
 Disease Specifics…………………………………………………………………………18 
 
Treatment……………………………………………………………………………………….29 
 Medication……………………………………………………………………………….29 
Isolation………………………………………………………………………………….31 
Directly Observed Therapy Short-Course……………………………………………….32 
Directly Observed Therapy Short-Course Plus………………………………………….37 
Treatment Strengths and Limitations…….................……………………………………38 
 
Complications…………………………………………………………………………………...47 
 HIV/TB Coinfection………………………………………………………………………..47 
 Treatment Concerns...……………………………………………………………………52 
 Drug Resistant Tuberculosis…….………………………………………………………..52 
 Treatment Concerns...……………………………………………………………………58 
 
Perceptions of Tuberculosis……………………………………………………………………63 
 Bacterial Isolation……………………………………………………………………….64 
 Isolation from the Community…………………………………………………………...66 
 Isolation from Family……………………………………………………………………72 
 Isolation from Self………………………………………………………………………..76 
 
Conclusion………………………………………………………………………………………81 
 
Works Cited……………………………………………………………………………………..87 
 
LIST OF FIGURES 
Figure 1………………………………………………………………………….……….Title Page 
Figure 2………………………………………………………………………….………………...9 
Figure 3………………………………………………………………………….………………...9 
Figure 4………………………………………………………………………….……………….18 
Figure 5………………………………………………………………………….……………….19 
Figure 6…………………………………………………………………………………………..26 
Figure 7…………………………………………………………………………………………..48 
Figure 8………………….………………….………………….………………….……………..55
1 
Acknowledgements          
 Thank you so much to all of my committee members who have guided me throughout my 
time writing this thesis. Dr. Pascal Lafontant (my sponsor), Dr. Sharon Crary, Dr. Rebecca 
Upton, and Dr. Marnie McInnes, I cannot thank you enough for your help and patience. I 
sincerely thank you for encouraging me to think about things from different perspectives and 
challenging my writing style. 
 Additionally, my thesis would not have been completed without the support of my family 
and friends. Thank you to my mom, Ingrid, and dad, Randy, for always listening to my struggles 
and excitements throughout this entire process. Thanks to all of my fellow honors scholars 
writing their theses as well that were a constant source of encouragement – Katie, Megan, 
Colleen, and Cody you helped me more than you know. 
 Finally, a huge “thank you” to my supportive and always loving inspirations, Oma and 
Opa. Your experiences have struck awe in me since I was a little girl, and I hope that my thesis 
can provide a small way to commemorate your immeasurable strength. I am honored to be 
related to two of the kindest, most compassionate, and absolutely incredible people I know. 
Liebe euch! 
 
 
 
 
 
 
 
2 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
3 
Preface             
 The sight of perfectly pressed curtains, the smell of schnitzel, and a feeling of 
overwhelming comfort meet me at the door of my grandparents’ condominium in Venice, 
Florida. I arrive in the late afternoon and am greeted by tight hugs, numerous kisses and a not so 
hidden once-over just to make sure that I am well. As is typical of Austrian culture at this time of 
day, we chat over a table of different kinds of cookies and a steaming hot pot of coffee, which 
was crocheted by my oma (grandmother) and is covered by a small coffee hat in Austrian colors, 
a vibrant red and brilliant white. As I look into my grandparents’ eyes it hits me. Never could a 
stranger guess the numerous hardships that my grandparents endured. Never would anyone 
assume that they were forced to sacrifice just about everything to achieve what they have now. 
Despite their jovial spirits, there is a story within each wrinkle and every sore joint. These stories 
have inspired me since I was a young girl and one of them in particular, the story of my oma’s 
mother, has motivated my study of tuberculosis.  
  My oma, Maria Bitner (now Katzfuss), was born in the tiny village of Illatscha in present 
day Austria but what used to be Yugoslavia. Illatscha was a small village inhabited by 
Donauschwaben, a group of Germans from a region bordering the Danube. My oma was born to 
Josef and Suzanne Bitner who later had one more child, Erwin. My great-opa, Josef Bitner, was a 
Tischler, or carpenter in English, in the village as well as a Grackel, or soda pop, maker. By 
Illatscha’s standards, the Bitner family was relatively well off. They lived on a large farm at the 
end of the Gasse, or street, that ran through the center of town. The village was primitive 
compared to today’s standards but living there was fulfilling and culturally rich nonetheless. 
Additionally, life in Illatscha was not without its hardships. Living as Donauschwaben in 
Yugoslavia gradually became more dangerous as Josef Tito and the communist Partisan Army, 
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or Partisaner as my oma calls them, became more powerful (“The Resistance Movement in 
Yugoslavia,” 2014). The Partisaner were not fond of Germans after the Nazis took over 
Yugoslavia. They invaded German villages in the dead of night to snatch away able-bodied men 
to work in camps in Siberia and rape their wives, sisters, and mothers. The Donauschwaben in 
Illatscha constantly lived in fear of an invasion. For that reason, my oma slept between her 
grandmother’s feet clutching tightly to a small sack containing her belongings every night. 
 Tragically, on October 14, 1944 the fears of an invasion were realized. A siren blew 
loudly throughout the village, and the Partisaner announced that Illatscha’s villagers had six 
hours to pack their belongings and leave Yugoslavia. My oma and her family quickly bundled up 
everything they could and fled. Running through the field of tall wheat, my oma desperately 
clung to her grandmother’s hand with one hand and onto her small sack containing her few 
precious belonging with the other. As they fled as fast as their feet could travel, a plane flew 
lowly overhead shooting at them and the other fleeing villagers. To this day my oma remembers 
this terrifying day as if it was yesterday. They left behind their farms, their church, their school, 
their jobs, and the only life my oma ever knew. 
Eventually, the Bitner family and other Illatscha villagers were loaded onto a cattle train 
to be taken to an undisclosed location. Would it be Siberia? Would it be a new place to start their 
lives? Luckily, after days upon days of traveling by cattle train as well as horse and wagon, the 
Bitner family and other villagers from Illatscha arrived in Linz, Austria where my family still 
lives today. Not everyone survived the long, dangerous, and arduous journey through 
Yugoslavia, part of Hungary, and much of Austria. However, those that survived were placed in 
the erste Lager, or the first building of the refugee camp at Linz. Here the Bitners waited to go 
through health screenings, be assigned to their respective jobs, and be given a barrack to live in. 
5 
They waited to learn what their future would hold in a large over-crowded room filled with 
families all anxiously awaiting the same thing. 
Eventually, my opa Bitner was assigned to work at the steel plant, and the Bitner family 
was given a one-roomed barrack to live in. This living arrangement was typical for the refugee 
camp in Linz. Entire families shared a single room heated by one source that doubled as both a 
furnace and a stove. A one-roomed schoolhouse was the only educational establishment 
available for children, and those that were fortunate eventually learned a trade. The women of 
the refugee camp cooked, cleaned, and worked if they were given a job. The men worked, 
usually in the steel plant, to provide for their families. Hearing my oma talk about life in Linz is 
like traveling back in time to a year and place that stands in such stark contrast to life in the 
twenty-first century. It hardly seems possible that one person could experience such extremes. 
Yet despite these struggles, there is a hint of nostalgia in her voice when she talks about life in 
Austria. 
Beyond any of the struggles and primitive physical surroundings that my Oma 
experienced in Linz, it is evident that she misses the proximity in which she lived to her family 
as well as being immersed in the rich Donauschwaben culture. Families spent almost all of their 
time together. They relied on each other for safety and provision, and helped each other in times 
of need. Unfortunately, when tragedy struck my oma’s family, there was nothing that other 
family members or neighbors could to do help. This tragedy took the form of a deadly disease 
that many people in the refugee camp were familiar with. In 1944, when my oma was five years 
old, her mother was diagnosed with tuberculosis. During the health screening process in the erste 
Lager as the family was in the process of gaining admittance into the refugee camp, she was 
given a chest X-ray that confirmed the diagnosis. 
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 Because much of the Bitner family’s wealth was left behind when they fled Illatscha, the 
family did not have abundant financial resources with which to ensure that my great-oma was 
given the best medical treatment available. However, she was under the care of the physician at 
the refugee camp who prescribed her medication. The disease did not seem to react to the 
medication, so she was removed from the Bitner household in order to prevent any other 
members of the village from contracting the disease. Suzanne, my great-oma, was admitted to a 
sanitarium when it was discovered that the medication was still not affecting her infection. When 
my oma was able to visit her mother, she interacted with her solely by looking at her through a 
large window. She saw her mother in a room containing many others suffering from tuberculosis. 
Quietly peering into the isolation room, my oma remembers the immense loss she felt. I can hear 
the pain in my oma’s voice as she describes what it was like to be separated from her mother at 
such a young age. She says that amongst all of the sick people in the sanitarium it was nearly 
impossible to recognize her mother. She was gaunt, thin, and looked ill just like the rest of the 
tuberculosis patients admitted to the sanitarium. My oma said that, from what she could 
remember, her mother had looked like “nothing but skin and bones” for some time before her 
diagnosisso it is difficult to know exactly how long my great-oma had been sick for.  
Although she was still alive, Suzann’s separation from the family was palpable, real, and 
almost overwhelming. Her absence left a large hole in the Bitner family. Without a mother in the 
household, the cooking, cleaning, and sewing duties fell onto my oma and her grandmother. My 
oma tells me how she missed her mother terribly. Her mother was loving, and a woman to be 
admired. My oma looked up to her, and her tuberculosis infection irreversibly separated my oma 
from her mother. “No child should have to go through that,” recounts my oma as she reminisces 
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on life during her mother’s illness. “Your Onkel Erwin didn’t even get to know his mother,” she 
explains.  
 Three and a half excruciatingly long years went by. My great-oma was still in the 
sanatorium and now my oma was nine years old. My great-opa had enough. Nothing could be 
done to rid Suzanne of the horrendous bacteria colonizing her lungs. It was already known that 
my great-oma would die of this disease, but she was adamant that the last months of her life 
would no longer be spent in a sanitarium. Although it was ill advised, my great-opa struck a deal 
with a nearby farmer. For a price, the farmer allowed my great-oma to live in a one-room storage 
structure on his land. So, my great-oma spent the final six months of her life being visited by 
family while staying in self-quarantine. Thankfully, my oma was able to see her mother, bring 
her food, and spend limited amounts of time with her there. 
 Six months after moving into self-quarantine, on October 23, 1948, Suzanne Bittner 
succumbed to tuberculosis. She died at age 28 leaving behind her husband and two young 
children. Slowly, the family healed. My great-opa remarried, my oma’s grandmother helped take 
care of the family, and life fell into a new rhythm. However, the devastating effects of the 
disease and its treatments left a lasting impact on my oma. Looking at her mother through the 
sanitarium window, bringing food to her house on the farm, and having to once again completely 
adjust her life after it was irreversibly altered are all as vivid to my oma now as they were then. 
Memories such as those are not easily forgotten. 
 After hearing my oma retell this story, I became more curious about tuberculosis. 
Questions about the disease itself, treatment option, and public health interventions continually 
came to mind. However, throughout my research on the topic it became apparent that in addition 
to specifics of the disease and its treatment, stigma seriously affects patients suffering from the 
8 
disease. Tuberculosis is associated with multiple stigmas and can be perceived differently within 
different cultural contexts, but some stereotypes of people with active tuberculosis infections are 
cross-culturally and internationally the same. Even in my oma’s re-telling of her mother’s 
struggle with the disease, concepts such as fear and isolation were repeatedly associated with her 
perception of her mother’s illness. Therefore, considering perceptions of tuberculosis as well as 
scientific information regarding the disease are both important components to understanding 
tuberculosis.   
 My great-oma’s story has inspired me to study tuberculosis. My oma has been curious 
about the disease, so hopefully through my research I will be able to explain more about it to her 
in order to contribute to her knowledge about her mother’s life. Both my oma and opa have 
taught me many things, things too numerous to count, that they have learned throughout their 
difficult yet inspirational lives. They are two of the strongest people I know, and I am blessed to 
be related them. They are two of my biggest role models. After writing Suzanne Bitner’s story 
and hearing my oma tell it again and again I was reminded of one lesson that both my oma and 
opa have taught me, which now rings truer than ever.  Family is one of the greatest gifts that we 
are given so cherish it because you never know where life will take you. 
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Figure 2. The wedding of Suzanne Strumberger (left) and Josef Bitner (right) in 1936. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3. The Bitner Family in front of their barrack in Linz, Austria. From left to right: 
Suzanne, Maria, Erwin, and Josef Bitner. 
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PRELUDE 
Even though my great-oma suffered from tuberculosis approximately half of a century 
ago, the disease still persists today. Many factors contribute to why tuberculosis plagues humans 
across the world. The two factors this thesis will address are strengths and limitations of current 
treatment programs and perceptions of the disease that hinder patients from being treated. 
Overall, there are many other factors that contribute to tuberculosis’s continued presence 
throughout human history as well, but they are beyond the scope of this thesis. 
This thesis is divided into two sections. The first aims to highlight disease characteristics, 
current treatment methods, and additional complications that can arise with tuberculosis 
infection. Building upon this background information, the first section includes analysis of the 
strengths and limitations of current treatment options. The goal of the second portion is to show 
the reader that tuberculosis’s damage extends beyond the physical wasting away of the patient’s 
body. The disease is a metaphor for isolation, which explains why the tuberculosis also 
emotionally scars its host. Finally, the thesis will conclude with connecting the first two portions 
in attempts to explain the interplay between the physical and emotional damage experienced by 
patients suffering from tuberculosis. 
 Ultimately, there is not one way to eradicate tuberculosis and solve all of the problems 
that it creates. There is not one treatment program, one miracle drug, or one stupendous leader 
that can eradicate the disease. Instead, based on my research, it seems as though ridding the 
world of tuberculosis will depend on culturally sensitive treatment methods that are focused on 
the patient. This might require additional resources, specifically financial and labor resources, 
but eradicating this disease will benefit the global population. 
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Background            
My great-oma, Suzanne Bitner, lived during a time when only a few of the currently used 
treatments were available, and the disease itself was not as understood as it is today. However, 
tuberculosis already had a rich history by the time she contracted the disease. The years in which 
she lived have guided me and served as benchmarks during my construction of a brief history of 
tuberculosis. The historical information and background details about the causal bacterium itself 
are necessary to clarify what TB disease is. This information is crucial to highlighting relevant 
disease specifics before analyzing how tuberculosis is being addressed today and what 
perceptions of the disease entail. The background information includes characteristics of the 
disease’s causal bacterium, symptoms of TB infection, and components of diagnostic tests that 
are used to ensure a patient is correctly diagnosed as having tuberculosis. 
 
HISTORY  
Tuberculosis has plagued human beings for centuries. Young and old, rich and poor, 
famous and otherwise have all suffered from this devastating disease. Ancient human 
populations first suffered from tuberculosis in Africa thousands of years ago. Then, it spread to 
South America by seals traveling across the Atlantic Ocean. Seals were a major food source for 
humans living in South America around 2,500 years ago. Therefore, when humans ingested a 
seal infected with tuberculosis bacteria, they contracted the disease themselves. After 
tuberculosis had reached South America, many different strains of the disease traveled the globe 
with their human hosts. As humans migrated to other areas of the world and settled in different 
locations, tuberculosis followed (Bos et al., 2014). These prehistoric movements set the stage for 
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the rest of tuberculosis’s history as one of the most infamous and tragic diseases in the history of 
humankind.  
 According to Thomas Daniel, MD (1999), who has written accounts of tuberculosis’s 
history after extensive study of the disease and experience with it, researchers discovered ancient 
remnants of the disease in the vertebrae of mummies preserved since pharaohs ruled Egypt (p. 
9). Specimens dating back to around 3000 BCE containing evidence of tuberculosis bacteria 
have been found in the town of Dra Abu El-Naga on the Nile River in Egypt as well as in 
Thebes. In these mummies, the characteristic sign that the individual suffered from a tuberculosis 
infection is the presence of abnormal lesions in the spine. Although these mummies provide an 
important key to recognizing how long people have suffered from tuberculosis, they are not the 
only evidence of early tuberculosis infections. Many Egyptian art forms from this era depict 
people suffering from the disease. The pieces of art depict individuals with hunchbacks, a telltale 
sign of tuberculosis infection in the spine (Daniel, 1999).  
Numerous other early tuberculosis cases in countries such as Peru, India, and China have 
been discovered that date back to around 2000-1300 BCE. These discoveries contained evidence 
of tuberculosis in the spine as well as the more commonly known lung infection of tuberculosis. 
Also, writings and other artifacts from these civilizations show that various communities had 
different names for tuberculosis. In India, ancient civilizations referred to it as yakshma, and in 
China it was called laoping. Hundreds of years later, after 460 BCE, the father of medicine, 
Hippocrates, addressed tuberculosis and provided additional insight into the treatment of the 
disease. Hippocrates called the disease phthisis and used this word in his case notes to describe 
tuberculosis (Daniel, 1999). Dr. Daniel (1999) mentions that Hippocrates’s notes, containing 
various observations regarding the physical manifestations and symptoms of the disease itself, 
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seem to correspond with current clinical presentations of the disease (p. 18). Hippocrates 
characterizes phthisis as the most widespread disease at the time, and warns his fellow 
physicians to stay away from patients with the infection (“A History of Tuberculosis Treatment,” 
n.d.).  
Other famous ancient physicians observed and wrote about tuberculosis. Arteus wrote 
about it in ancient Greece around 200 BCE, and Galen studied it ancient Rome. However, 
following these writings there was a gap of 1,000 years, during the Middle Ages, in which 
tuberculosis discussion was sparse. Interestingly, the most talked about form of tuberculosis 
discussed in writings from this age were not the infections present in the lungs or spine. The 
most commonly discussed form of tuberculosis from this time was called scrofula (Daniel, 
1999).  Dr. Daniel (1999) highlights the familiarity with which scrofula was discussed by 
mentioning that even Shakespeare includes it in Macbeth (p. 24). In patients suffering from 
scrofula, the lymph nodes become swollen but are still relatively painless (“Scrofula,” 2015). 
This term is still used today to describe this specific manifestation of tuberculosis characterized 
by the infection of the lymph nodes with the tuberculosis bacteria.  
For the next hundred years, bouts of tuberculosis came and went claiming many lives 
along the way. Tuberculosis deaths were at their highest in England in 1780 when one-quarter of 
the population died of tuberculosis. Although the death rate was not as high, tuberculosis was 
still present in the nineteenth century. In addition to Shakespeare, Dr. Daniel (1999) explains to 
readers that many famous individuals, such as members of the Brontë family and other notable 
artistic and literary figures, died of the disease that was commonly referred to then as 
“consumption” (p. 30). However, on March 24, 1882, a monumental step was taken in curing the 
disease. On this date, Robert Koch announced that he had discovered the bacterium responsible 
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for tuberculosis. Koch’s identification of the bacterium Mycobacterium tuberculosis as 
tuberculosis disease’s causal agent was the first step in a long journey to accurately diagnose and 
treat the disease (Centers for Disease Control and Prevention [CDC], 2014a).  
After Koch’s Nobel prize winning discovery of M. tuberculosis, several other physicians 
and researchers used this information to experiment further with the bacteria. For example, in 
1907, Clemens Freiherr von Pirquet, the pediatrician responsible for discovering serum sickness 
as well as creating the terms allergy and allergen, injected himself just under the skin with 
diluted tuberculin. Von Pirquet continued to experiment with tuberculin and injection dosages 
for the next two years. Based on the information he gathered from his experimentation, von 
Pirquet discovered a maximum amount of tuberculin that could be injected into an individual 
without them contracting the active disease. Interestingly, he realized that injecting this amount 
of tuberculin into children who did not suffer the full symptoms of the active disease allowed 
him to determine whether or not they had an unknown latent infection of tuberculosis bacteria 
(Daniel, 2006). A few years after Clemens Freiherr von Pirquet’s discovery, in 1919, my great-
oma Suzanne Bitner was born. Therefore, her story begins while researchers were still learning 
about fundamental aspects of the disease. A little more than ten years after my great-oma was 
born, in the 1930s, Florence Seibert expanded upon Clemens Freiherr von Pirquet’s discovery. 
Siebert formulated a purified protein derivative (PPD) of tuberculin. PPDs are still used in a 
simple skin test to determine whether or not an individual has latent tuberculosis (Daniel, 2006).  
Although the discovery of the PPD was and still is extremely helpful to diagnose cases of 
latent tuberculosis, creating an effective and sustainable treatment solution remained elusive. 
Other treatment methods that did not rely on medications were explored. Years before the 
discovery of the PPD, in the 1850, sanatoriums were established all over the world. Many 
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tuberculosis patients, including my great-oma, were admitted to sanatoriums after being 
diagnosed with active tuberculosis infections. These facilities attempted to provide their 
inhabitants with a good diet, exercise regime, and restful environment that would supposedly 
allow people suffering from the disease to recover. Tuberculosis patients did find respite in these 
places, but whether or not sanatoriums played a role in curing them of the disease is unknown 
(Daniel, 2006).  
Despite the questionable effectiveness of sanatoriums, it was not until the twentieth 
century that scientists began to achieve some success in the development of tuberculosis 
vaccinations. In 1921, Albert Calmette and Camille Guérin developed the BCG vaccine. They 
noticed that cattle could suffer from tuberculosis, but the Mycobacterium bovis bacteria rather 
than Mycobacterium tuberculosis bacteria caused tuberculosis in cattle. Calmette and Guérin 
cultured a weakened strain of M. bovis and injected this into people suffering from tuberculosis 
to heal them. It was unclear what drugs my great-grandmother was given even after speaking 
with my oma about her mother’s battle with tuberculosis. Since my oma was young when her 
mother was ill, she could not remember if her mother received the BCG vaccine. However, it 
was a widely used vaccine during this time. Its immediate efficacy resulted in thousands of 
people, adults and children alike, being vaccinated with the new BCG vaccine (Daniel, 2006). 
As the twentieth century progressed, new potential tuberculosis treatments arose while 
BCG was being used to vaccinate individuals. In 1943, Jorgen Lehmann discovered para-amino 
salicylic acid (PAS) and Gerhard Domagk created thiosemicarbazone. Both of these drugs 
became the first effective agents to treat tuberculosis.  Unfortunately, these drugs only stopped 
M. tuberculosis from replicating without actively killing the bacteria that were already present in 
the infected individual. Although it was an important step toward curing people of tuberculosis, a 
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more effective and potent killing agent was necessary in order to rid a patient of tuberculosis. In 
1944, the answer to this need was discovered. Albert Schatz, Elizabeth Bugie, and Selman 
Waksman announced their discovery of the antibiotic streptomycin. Streptomycin was more 
effective than either PAS or thiosemicarbazone because it killed the M. tuberculosis bacteria 
instead of solely halting its replication. As streptomycin continued to be used to combat 
tuberculosis, more medications were formulated, and tuberculosis treatment radically changed. 
Unfortunately, my great-grandmother lost her struggle with tuberculosis in 1948, not long after 
the Bitner family arrived at the refugee camp in Linz. I do not know whether or not she received 
streptomycin as part of her treatment regimen, but she passed before being able to reap the 
benefits of newer antibiotics developed to fight tuberculosis. The 1950s brought isoniazid and 
rifamycins, thus beginning an era of new drug therapies available to treat the disease and 
improve patients’ survivability (Daniel, 2006).  
The development of vaccines and antibiotics was not the only way to attack tuberculosis. 
Many campaigns were launched to raise awareness of the disease and raise funds to continue to 
research ways to eradicate tuberculosis. For example, in 1948, the year in which my great-
grandmother died, UNICEF and the Danish Red Cross sponsored a campaign to control 
tuberculosis. Beginning in Poland, spreading across Europe, and eventually reaching Ecuador, 
the International Tuberculosis Campaign resulted in 30 million people being tested for 
tuberculosis and 14 million people being vaccinated with BCG in only three years. This 
campaign was the first disease control program that an agency of the WHO, World Health 
Organization, undertook (Daniel, 2006).  
Since then, many different organizations have attempted to combat tuberculosis. The 
WHO frequently publishes reports on tuberculosis and developed the Stop TB Strategy, which 
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builds off of previously developed treatment methods in order to continue to create effective 
ways to rid humans of this tragic disease (World Health Organization [WHO], 2015a). The 
Global Fund funnels billions of dollars to local program across the globe to improve the 
treatment options for people suffering from this disease (“The Global Fund,” 2015). High profile 
donors, such as the Bill and Melinda Gates Foundation, donate thousands of dollars to many 
organizations and programs designed specifically to address tuberculosis (Bill & Melinda Gates 
Foundation, 2015). Overall, strategies to combat this ancient disease have significantly improved 
and continue to work to fight it. 
All of these international strategies and advancements in medicine development are 
helpful, but they are not enough. In 2013, 9 million people contracted tuberculosis, and 1.5 
million died from it.  Even more devastating is the fact that most of these deaths are preventable. 
Tragically, this ancient disease still plagues humans across the globe in the twenty-first century 
(WHO, 2015b). The image below shows the incidence rates of tuberculosis in 2012. As this 
image clearly shows, tuberculosis is still a concern in the twenty-first century.  
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Figure 4. Estimated TB Incidence Rates, 2012. Adapted from StopTB.org, n.d., Retrieved 
November 12, 2014, from http://www.stoptb.org/countries/tbdata.asp. Copyright 2015 by 
UNOPS. 
 
DISEASE SPECIFICS 
 Before further analysis of tuberculosis can occur, information about the tuberculosis’s 
causal agent is necessary for understanding the disease. As mentioned in the previous section, 
tuberculosis is caused by an infection of the bacterium Mycobacterium tuberculosis. M. 
tuberculosis is a rod-shaped bacteria, or bacilli, which is both non-motile and acid-fast. Each 
bacterium is usually 2-4 micrometers in length and 0.2-0.5 micrometers in width (Todar, 2012a). 
An important characteristic of M. tuberculosis that is crucial to understanding the way that the 
bacteria act when they infect a host is that the bacteria grow incredibly slowly. Their generation 
time is usually between 15-20 hours whereas many bacteria have generation times lasting in 
minutes (Todar, 2012b).  
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Figure 5. M. tuberculosis Bacilli. Adapted from the National Institute of Allergy and Infectious 
Diseases, 2012, Retrieved February 20, 2015, from http://www.niaid.nih.gov/topics/ 
tuberculosis/understanding/pages/cause.aspx.  
 
Additionally, M. tuberculosis is an obligate aerobe. Bacteria classified as obligate aerobes 
need oxygen to grow (“Obligate Aerobe,” 2015). Therefore, these bacteria are usually found in 
environments that provide the bacteria with a consistent and sufficient source of oxygen. For 
example, M. tuberculosis usually infects humans’ lungs, which provide an environment saturated 
with oxygen that is conducive to M. tuberculosis’s metabolic requirements. Specifically, after the 
infection has occurred, these bacteria usually concentrate and begin to grow in the upper regions 
of the lungs. The upper regions of the lungs are well aerated which perfectly satisfies the 
requirements of this vicious obligate anaerobe (Todar, 2012a). 
 A tendency to cluster in the oxygen rich area of the upper lungs is not the only 
characteristic of the bacteria that helps it thrive in its human host. M. tuberculosis is one of many 
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bacteria classified as facultative intracellular bacteria. The “facultative” portion of this descriptor 
means that the bacteria can replicate both inside and outside of cells. (“Facultative Anaerobe,” 
2015). Typically, M. tuberculosis lives and grows within macrophages, cells that engulf and 
destroy pathogens and other molecules tagged for destruction (Todar, 2012b). Therefore, if M. 
tuberculosis infects these immune cells, there are serious implications for immune function. It is 
incredibly ironic that the cells responsible for killing things that invade and potentially harm the 
human body are the ones usurped by this fatal agent.  
 Unfortunately, it is relatively easy to become infected with M. tuberculosis. The bacteria 
are spread from a host with an active and contagious tuberculosis infection to another individual 
through the air. For this reason, tuberculosis is considered to be an airborne disease. When an 
infected individual with active and contagious TB coughs, sneezes, or even speaks, bacteria are 
launched into the air. Luckily, every time an infected individual coughs, sneezes, or speaks it is 
not guaranteed that someone around them will contract tuberculosis. Specific factors affect the 
likelihood of being infected with tuberculosis. Susceptibility of the potential host, the 
infectiousness of the infected individual, and the surrounding environment all contribute to 
tuberculosis transmission. If a potential host is immune-compromised, they are more susceptible 
to contracting the disease. If the infected host releases a lot of the bacteria instead of only a few 
bacilli, it is more likely that people surrounding them will become infected. Also, if a potential 
new host is around an individual with active tuberculosis for a long time and is in proximity to 
them, the chance that this individual will become infected with tuberculosis increase. Airborne 
tuberculosis bacteria can stay in the air for several hours making the bacteria even more likely to 
be inhaled by another potential host (CDC, 2014b). 
21 
As if contraction of the disease did not involve enough steps to be taken into account 
when considering ways to treat the disease, tuberculosis’s behavior in the body is multi-faceted 
as well. The growth and presentation of tuberculosis can be broken down into four main phases. 
The first stage, transmission of the bacteria, begins with the new host inhaling M. tuberculosis 
bacteria. Next, the bacteria are ingested through the new host’s mouth or are inhaled through the 
nasal passages. Once ingested, the bacteria travel through the upper respiratory tract, reach the 
bronchi, and end their journey upon reaching the alveoli of the lungs. This process usually takes 
one week. Once the bacteria reach the macrophages in the alveoli, infection begins (Todar, 
2012c). Once in the alveolar sacs, M. tuberculosis is ingested by macrophages, immune cells 
responsible for engulfing and degrading pathogens, and other foreign substances. Depending on 
the size of the bacteria and the macrophage’s strength, macrophage ingestion of M. tuberculosis 
does not ensure destruction of the bacteria (Müller, 2011). 
If the macrophages in the alveoli do not kill M. tuberculosis, stage two of the disease 
usually begins about three weeks after initial infection of the patient. At the beginning of this 
stage, macrophages continue to engulf the bacteria, and the bacteria exponentially replicate 
within them. Once they can no longer accommodate the replicating bacteria, the macrophages 
burst, and M. tuberculosis spills out into the surrounding tissue. As the macrophages overflow 
with TB bacteria, other immune cells are recruited to address the issue. A cell-mediated immune 
response initiates the recruitment of T cells and other leukocytes to the lungs so an inflammatory 
response can begin. Additionally, at this phase of the disease, an infected individual will test 
positive for tuberculosis when a PPD skin test is administered (Müller, 2011). 
As exponential replication of M. tuberculosis wanes, the disease enters its third stage. 
After the bacteria kill the macrophages surrounding them, the host environment immediately 
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surrounding the bacteria and macrophages becomes anoxic and acidic. Therefore, bacterial 
replication gradually comes to a stop, and the lungs sequester the bacteria in this region. At this 
point, the infection is controlled and stabilized. If an individual at this point of infection coughs, 
bacteria will not be launched into the surrounding air because the bacteria are restricted to 
specific clusters within the lungs. In other words, they are no longer contagious, which is 
fascinating because the individuals are still infected with the bacteria. The clusters in which M. 
tuberculosis congregates are called tubercles (Todar, 2012c). Tubercles are hard, slightly round 
regions of tissue made up of dead cells with M. tuberculosis at the center, and they are 
characteristic of tuberculosis infections (“Tuberculosis (TB),” 2015). The bacteria can stay 
within tubercles for years. The acidic and anoxic environment keeps the bacteria from 
replicating, so the bacteria are unable to leave these clusters within the lungs. An individual with 
tubercles in their lungs is said to have a latent tuberculosis infection or primary TB (Müller, 
2011).  
Tuberculosis does not always stop at this asymptomatic primary TB phase, thus making 
the disease significantly more frightening. Some patients with latent tuberculosis have additional 
health concerns that allow TB bacteria to re-activate and enter stage four. For example, patients 
whose immune systems weaken some time after their latent tuberculosis established itself are at 
risk for their TB bacteria re-activating. Also, patients who are immune-compromised before 
coming in contact with the tuberculosis bacteria might incur a TB infection that never enters the 
latent stage and continues to progress to stage four without stalling at stage three. Whatever the 
case may be, primary TB can become active TB. Once an individual has active tuberculosis, they 
are considered to be in stage four of tuberculosis infection. Once activated, M. tuberculosis 
bacteria rapidly replicate again and quickly spread through the lungs using the host’s immune 
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cells to spread. In some cases, the bacteria leave the lungs and infect other parts of the body. For 
example, as was seen in mummies found in ancient Egypt, infection of the spine with 
tuberculosis bacteria can potentially occur if tuberculosis is left untreated. When a patient suffers 
from active tuberculosis, they are contagious once again. Every cough, sneeze, or other related 
activity results in the spewing of infectious M. tuberculosis into the air waiting to be inhaled by a 
new host. If left untreated, active tuberculosis is potentially fatal (Müller, 2011). 
Although symptoms depend on which stage of infection a patient’s tuberculosis is in, 
there are a few characteristic signs of the disease, mostly associated with the active form, which 
are noteworthy. When a patient has latent tuberculosis, he or she does not have any symptoms. 
About 2 billion people have latent tuberculosis. Despite the lack of symptoms, patients with 
latent tuberculosis are still urged to seek treatment so that they do not develop active tuberculosis 
in the future. On the other hand, patients with active tuberculosis present with symptoms that are 
commonly associated with the disease. These symptoms include coughing, chest pain, and 
among others. If the tuberculosis infection spreads to other bodily structures, the patient will 
suffer from additional symptoms depending on what other organs are tissues are affected. For 
example, if tuberculosis infects the spine, back pain might follow. Also, if tuberculosis affects an 
organ such as the kidneys, bloody urine could ensue (Mayo Clinic, 2014).  
The symptoms associated with tuberculosis are very indicative of active tuberculosis 
disease, but diagnostic tests are performed on individuals to confirm the diagnosis. Medical 
health professionals use a variety of tests when diagnosing a patient with tuberculosis. The tests 
employed to diagnose a patient with tuberculosis usually include a TB skin test or TB blood test. 
Depending on the results of these tests, additional methods such as a chest X-ray or a more 
specific bacterial test are administered to confirm the diagnosis (CDC, 2014c). 
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A TB skin test, or the Mantoux tuberculin skin test, is an easy and relatively non-invasive 
test. The tests are relatively painless, which seems to be small price to pay to determine whether 
or not an individual has this potentially life-threatening disease. A small amount of tuberculin, 
which is an extract of M. tuberculosis, is injected under the skin of the patient’s lower forearm. 
Once injected, a small bubble is visible under the skin. Within 48-72 hours, a reaction to the 
tuberculin will or will not have occurred. After this allotted amount of time, the patient has a 
medical professional read the skin test and declare it either positive or negative. If the test is 
positive, a raised red bump where the tuberculin was injected will be visible. The injection site 
will be slightly swollen, and the injection point will feel hard upon palpation. A positive TB skin 
test means that the patient has tuberculosis, and additional tests will be administered to confirm 
this preliminary diagnosis or treatment will being. On the other hand, a negative TB skin test is 
characterized by the absence of any characteristics associated with a positive result, such as 
hardness and swelling at the tuberculin injection site. If a patient’s TB skin test is negative, the 
patient most likely does not have active or latent tuberculosis (CDC, 2014d).  
A TB blood test can also be administered as a preliminary test to determine whether or 
not a patient has tuberculosis. TB blood tests are usually performed on patients that continually 
do not return to see a medical professional after their TB skin test has been administered or 
patients that have been vaccinated with the BCG vaccine. Many countries still vaccinate their 
citizens with BCG to protect them from a tuberculosis infection. However, this vaccination 
involves injecting a form of Mycobacterium into the patient. Ironically, patients vaccinated with 
BCG and later receive a TB skin test will have a positive reaction to the injected tuberculin. 
Although biologically this is logical, it seems contradictory for an individual to test positively to 
a diagnostic test because of a vaccine. TB blood tests, or interferon-gamma release assays, 
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determine whether or not M. tuberculosis is present in the individual based on how the patient’s 
immune system responds when it comes in contact with the bacteria. Blood is extracted from an 
individual and is exposed to M. tuberculosis in the lab. Then, the strength of the immune 
response in the presence of the bacteria is measured. A positive IGRA means that a person has 
M. tuberculosis bacteria in their body whether as a latent infection or an active one. Additional 
tests are required to determine which form of the disease is present. A negative IGRA means that 
the patient has no M. tuberculosis in their body and therefore does not have latent or active 
tuberculosis (CDC, 2014e).  
Another way to determine whether or not an individual is infected with tuberculosis is to 
perform a chest X-ray. Medical professionals take posterior-anterior images of a person’s chest 
in order to locate any abnormal regions in the lungs. Usually, lesions indicative of tuberculosis 
infection will be visible on these images. X-ray images have been used to diagnose tuberculosis 
for decades. Before gaining admittance into the refugee camp at Linz, my oma and her family, 
like all incoming individuals, were required to pass a health-screening test before living in the 
camp. It was during her health screening test, which included a chest X-ray, that my great-oma 
received her diagnosis of tuberculosis. There is a significant amount of variance in lesion size, 
shape, and density in radiographic images, so an X-ray is helpful to rule out false positive TB 
skin and blood tests. If a chest X-ray contains abnormalities, additional tests are usually 
performed to formulate a more concrete and confident diagnosis (CDC, 2011d).  
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Figure 6. Chest X-ray of a Patient with Tuberculosis. Adapted from MedlinePlus, September 1, 
2012, Retrieved November 12, 2014, from http://www.nlm.nih.gov/medlineplus/ency/ 
imagepages/1607.htm. 
 
The final diagnostic test that could be used to determine whether or not a patient is 
suffering from tuberculosis is acid-fast microscopy. Once again, M. tuberculosis has a strategy to 
avoid easy detection, thus supporting its survival. M. tuberculosis is an acid-fast bacteria 
meaning that the bacteria cannot be dyed with some dyes used for microbiological staining. 
Therefore, acid fast bacteria would not be as visible when observed under a microscope. The 
outer coat of M. tuberculosis does not allow the dye to bind to the cell, so normal staining 
procedures are unhelpful. Specific methods, such as the Ziehl-Neelsen stain, are used instead. 
The Ziehl-Neelsen staining method requires that M. tuberculosis be smeared and fixed onto a 
slide where it is stained with carbon-fuchsin dye, decolorized with acid-alcohol, and then 
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counterstained. When stained using the Ziehl-Neelsen method, M. tuberculosis will appear pink 
when observed under a microscope (Todar, 2012a). However, M. tuberculosis is not the only 
acid-fast bacterium. So, when a procedure such as the Ziehl-Neelsen method is performed and 
pink acid-fast bacteria are visible, the visible bacteria is cultured to determine whether or not M. 
tuberculosis is present. If the culture contains M. tuberculosis, the patient is diagnosed as having 
TB disease (CDC, 2011d). After a TB disease diagnosis is confirmed, treatment is the next step 
in curing the patient of tuberculosis. 
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Treatment            
 After receiving a diagnosis of tuberculosis, patients must receive proper and effective 
treatment as soon as possible. A variety of treatment procedures are available for patients. 
Almost always, drug therapy is prescribed and it requires patients to take a variety of drugs for 6-
9 months (CDC, 2012a). However, drug therapies are not the only treatment options for patients 
suffering from tuberculosis. Isolation, a treatment method used in my great-oma’s case, is a 
widely used method in addition to medications. Highlighting the drug therapies and additional 
treatment methods associated with tuberculosis is important because they are the root of many 
controversies and problems regarding why humans still suffer from the disease. The available 
treatment methods for patients with tuberculosis as well as their strengths and limitations will be 
discussed in this section.  
 
MEDICATION 
 Decades of research have been dedicated to creating anti-tuberculosis drugs, and many 
have been developed. Interestingly, not all are frequently distributed. Although many drugs are 
approved as safe and effective treatment methods, only four drugs are the most widely used to 
treat tuberculosis. These four drugs are isoniazid, rifampin, ethambutol, and pyrazinamide (CDC, 
2012a). Isoniazid interferes with M. tuberculosis replication and metabolism. The drug does not 
allow the bacteria to make mycolic acids, which are necessary when forming the bacterial cell 
wall. Also, isoniazid interacts with a bacterial enzyme so that M. tuberculosis cannot properly 
metabolize (“Isoniazid,” n.d.). Rifampin impedes the function of bacterial RNA polymerase. It 
binds to an enzyme so that RNA polymerase cannot transcribe DNA (Wehrli, 1983). Ethambutol 
does not allow the formation of metabolites necessary for M. tuberculosis replication. However, 
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it is only effective in bacterial cells that are actively replicating. Additionally, it is involved in the 
killing of M. tuberculosis cells (Forbes et al., 1962). Lastly, pyrazinamide works against M. 
tuberculosis by interfering with its membrane’s ability to transport substances. Not much else 
about pyrazinamide’s function is known (Zhang et al., 2003).  
Tuberculosis medications are administered differently for patients suffering from latent 
infections and those suffering from active infections. The recommended drug regimens for 
patients with latent infections involve taking one or two drugs for a specific amount of time. The 
most frequently prescribed regimen for individuals suffering from latent tuberculosis infection 
requires the patient to take isoniazid daily for nine months. This regimen is usually prescribed for 
children and patients also infected with HIV (CDC, 2012b).  
Another potential treatment that can be administered involves a combination of isoniazid 
and rifapentine, a drug that does not allow RNA polymerase to transcribe DNA (Munsiff et al., 
2006). This combinatorial treatment is divided into 12 doses taken over the course of three 
months. The isoniazid and rifapentine regimen is recommended for specific patients. Individuals 
12 years and older who are healthy other than their latent TB infection and who are highly likely 
to develop active TB disease in the near future are usually given this regimen. The last 
recommended treatment requires that patients take rifampin daily for four months. This regimen 
is divided into a minimum of 120 doses. Alternative drugs, dosages, and times are available 
depending on specific patient needs, but these are the treatments most commonly diagnosed for 
patients suffering from latent tuberculosis infections (CDC, 2012b). Regardless of which drug 
regimen is administered, each one is complicated and involves a significant amount of planning, 
thus making tuberculosis drug therapy a potentially difficult task. 
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 Patients suffering from active TB disease are treated differently than those with latent 
infections. However, the drug regimens remain complex and time dependent. Although the drugs 
involved are largely the same, treatment regimens are divided between two phases, the initial 
phase and the continuation phase. The recommended treatment requires patients to take 
isoniazid, rifampin, ethambutol and pyrazinamide daily in 56 doses over the course of eight 
weeks. These eight weeks fulfill the initial phase of treatment. The continuation phase, which is 
not required for all patients, follows the initial phase and lasts between four and seven months. 
This phase requires patients to take isoniazid and rifampin daily for 126 doses over eight weeks. 
Alternatively, the patient can take isoniazid and rifampin twice a week for 36 doses over 18 
weeks. Patients are usually suggested to complete the four-week continuation phase regimen, but 
this is not necessary in all cases (CDC, 2012b).  
The initial and continuation phases mentioned above are the regimens that are preferred 
and most commonly administered. However, successful alternative treatments are also available 
if necessary (CDC, 2012b). New treatments are currently in trial phases (“Working Group on 
New TB Drugs,” 2015). Hopefully, these new drugs will begin to rid the patient of the disease 
sooner than the drugs currently used, destroy drug-resistant bacterial strains, and cause fewer 
side effects for the patients taking them. 
 
ISOLATION 
 Historically, tuberculosis was not always treated with drugs. Rifampin, isoniazid and 
many of the other drugs used to cure tuberculosis in the twenty-first century were not an option 
for many patients suffering from tuberculosis throughout history. The development of other 
methods to decrease the spread of tuberculosis was necessary. One method that has been used for 
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decades and is still used in some cases today is isolating a patient with active tuberculosis. 
Isolation is the separation of a patient who is contagious and has already been diagnosed as being 
infected with tuberculosis. A standardized way to isolate patients was first used in the Middle 
Ages and has been used ever since (CDC, 2014f). Whereas drug therapies wreak havoc on a 
patient’s body, isolation can cause significant emotional damage to an individual. Because of 
this, isolation continues to be an incredibly controversial treatment strategy that many consider to 
be unethical. 
 However, many large organizations involved with tuberculosis treatment support 
isolation as an important step in addressing tuberculosis infections. The Stop TB Strategy, a 
strategy created by the WHO to reduce the spread of tuberculosis, published a pamphlet for 
patients with infectious tuberculosis. The pamphlet explains what patients should expect 
regarding TB and its treatment. An entire chapter is devoted to preparing patients for isolation if 
it becomes a necessary step in their treatment (Thorn, 2007).  Paul Thorn (2007), the author of 
the pamphlet, states, “Many people who have been through the isolation experience say that it is 
the hardest part of having TB” (p. 14). Isolation rooms are characterized as small, potentially 
under negative pressure, and usually with a phone. In isolation, a patient’s diet is most likely 
different from what they are accustomed to and exercise is encouraged if the room size allows. 
According to the Stop TB pamphlet, isolation usually lasts between 14-30 days and can be an 
emotionally taxing experience (Thorn, 2007). 
 
DIRECTLY OBSERVED THERAPY SHORT-COURSE 
Fortunately, isolation is not the only method available to stop the spread of tuberculosis.  
Other methods have been incorporated into standard tuberculosis treatment methods that work in 
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conjunction with drugs to effectively kill M. tuberculosis and cure patients of TB disease by 
extension. The WHO has created DOTS, or directly observed therapy short-course, as a way to 
guide nations toward decreasing the incidence and prevalence of tuberculosis across the world. 
DOTS can be broken down into five main elements. These elements include the presence 
political commitment and consistent financing, better diagnosis and detection of cases, 
supervision and support for patients receiving treatment, enough medication and trained people 
to manage them, and a system that can track the disease as well as its impact on communities 
that it affects (WHO, 2015a). As is evident through these components, DOTS is a multifaceted 
approach to address issues associated with tuberculosis ranging anywhere from small-scale 
interventions such as patient support to larger scale interventions such as political involvement.  
The first element of DOTS, political and financial commitment, calls for governmental 
commitment to curing tuberculosis by being consistently involved and increasing their financial 
support. When governments of different countries show dedication to the same goal, the 
eradication of tuberculosis, in this case, supportive and beneficial partnerships can form between 
them. The partners can begin to develop strategies together that will improve tuberculosis 
treatment availability as well as many other factors that can bring local communities and the 
greater international community one step closer to eradicating this disease. A large part of what 
political involvement can do to benefit tuberculosis treatments is providing continual and 
substantial funding. Proper financing for sufficient and good quality tuberculosis treatments for 
all people that need it begins with political commitment. Once governments have addressed 
tuberculosis domestically, international partnerships can provide additional assistance and 
support where necessary. All of these suggestions for political involvement are considered with 
the main goal to ensure that TB patients are able to receive treatment (WHO, 2015a).  
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The second element of the DOTS therapy is to be able to more efficiently and accurately 
diagnoses cases of tuberculosis using better detection methods. As mentioned in the previous 
chapter, one of the ways to determine whether or not a patient is infected with M. tuberculosis is 
to perform acid-fast microscopy and culture the acid-fast bacteria. If M. tuberculosis is present in 
the culture, then the individual is diagnosed as being infected with tuberculosis bacteria. Acid-
fast microscopy is an effective and accurate way to diagnose TB disease.  Unfortunately, not 
everyone has the luxury of receiving these tests let alone receive them in a timely manner. 
Therefore, it is necessary for labs that are better equipped with the proper technology and trained 
lab personnel to be accessible to all patients who need these services. All of these labs should 
follow international guidelines as well as provide staff with routine training in order to ensure 
that patients are treated properly (WHO, 2015b). Eventually, if element two is put in place, case 
detection rates should improve and more immediate treatment of infected patients will follow. 
The third element of the DOTS strategy is that patients need to be supplied with standard 
treatments and should be supported in completing their respective treatments. Standardizing 
treatments requires medical professionals to provide their patients with the recommended drug 
regimens and dosages. The WHO made this information available and provided guidelines 
regarding standardized treatment that are accessible to medical professionals. Standardizing 
treatment across the globe benefits the global community for many reasons. One of the main 
reasons that treatment should be standardized is that it will reduce the development of new multi-
drug resistant strains of tuberculosis. Since multi-drug resistance strains are often incurable, 
doing anything possible to reduce the occurrence of these strains is incredibly beneficial (WHO, 
2015c). 
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The third element of the WHO’s recommended DOTS program involves providing 
patients will support and supervision while they are receiving treatment for tuberculosis. One of 
the main reasons that multi-drug resistant strains of M. tuberculosis develop is because of non-
compliant patients. Some patients do not finish their drug regimens or only take them at 
intermittent times rather than at regular time intervals like they are suggested to do. In order to 
eliminate this behavior, observing patients as they take their medication is a suggested way to 
ensure patient compliance. Observation can be done anywhere and by any trained individual that 
the patient allows to supervise them. This method keeps patients accountable for taking their 
medication as well as ensures that providers are properly administering medications. Lastly, this 
element suggests that support group for patients in need could also be a beneficial addition to 
tuberculosis treatments (WHO, 2015c). 
As part of this third element of the WHO’s DOTS program, patients are supervised while 
receiving their tuberculosis medication through Directly Observed Therapy (DOT). DOT has 
been used extensively because of its efficacy in increasing the tuberculosis cure rates. DOT 
requires a trained healthcare professional or other individual to watch a patient receiving 
tuberculosis treatment swallow every pill in the correct dosage on the designated treatment days 
to ensure that the patient is taking their medication appropriately. This usually involves ensuring 
that the patient takes four anti-tuberculosis drugs five days a week for two months. After 
completing the two months of initial treatment, the patient will most likely take isoniazid and 
rifampin once a day for three to five days every week for an additional four to seven months 
(Friedland et al., 2004). DOT is not always employed when a patient receives treatment for 
tuberculosis, but there are some groups of patients for whom this therapy is recommended. 
Patients suffering from drug-resistant strains of tuberculosis, those receiving treatment 
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intermittently, and patients considered likely to not adhere to the guidelines of taking 
tuberculosis drugs are those enrolled in DOT programs. Potentially noncompliant patient 
populations usually include homeless patients, children, those that abuse drugs or alcohol, and 
patients suffering from disabilities. Additionally, individuals with latent tuberculosis infections, 
specifically those that are at a higher risk to develop an active infection, can also undergo DOT 
(CDC, 2012c).  
There are multiple components of Directly Observed Therapy programs to ensure that 
patients are monitored when receiving tuberculosis treatment. DOT requires the healthcare 
worker or other designated individual to check the patient for side effects, verify that the correct 
medication and correct dosage will be given to the patient, watch the patient swallow the entire 
dose, and finally document the patient’s visit. Some DOT programs go beyond these few steps. 
They help patients keep their appointments, provide incentives that encourage patients to 
continue treatment, and even provide transportation to and from the location that provides DOT. 
This location does not need to be in a medical clinic. DOT is usually given in a health care 
facility, referred to as clinic-based DOT, but field-based DOT is also an option for patients. 
Field-based DOT is defined as DOT provided to patients outside of a healthcare facility. It can 
be performed anywhere that is agreed upon by the patient and the individual providing the DOT. 
Locations such as at the patient’s home or workplace are commonly used (CDC, 2012c). 
Even if patient support and adequate supervision is available, tuberculosis treatment will 
be non-existent if drugs are unavailable. Therefore, the fourth pillar of the DOTS program is that 
enough drugs should be available for patients in need, and a management system should be in 
place in order to administer these drugs effectively. This element mostly concerns healthcare 
facilities. It challenges these facilities to have a reliable way of receiving the correct drugs in 
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necessary amounts so that they can be properly distributed to patients in need. Interestingly, this 
element states that anti-TB drugs should be free for all who need them. By providing these drugs 
free of charge, the WHO states that society as a whole will benefit because tuberculosis 
transmission to others will become less of a concern (WHO, 2015d). 
The final element of the DOTS strategy is that a system that can track the disease as well 
as its impact on communities that it affects. Recording and reporting systems are necessary to 
fulfill this element. These systems would be extremely beneficial because they will allow 
governments and health facilities to track tuberculosis so that they can address the proper areas 
in need of assistance. The way that data, including patient information and the treatment method 
used, is reported and recorded should be the same. After standardization is implemented, these 
records can be compiled after a stated amount of time and compared to older records to reach 
conclusions about the current state of tuberculosis in that region. If standardization of the 
information is achieved, then it can be easily read and analyzed. Although this element will 
require additional staff training to ensure that all people are aware of the proper way to report 
information, this element will provide information that will positively influence tuberculosis 
treatment and outcomes in the future (WHO, 2015e). 
 
DIRECTLY OBSERVED THERAPY SHORT-COURSE PLUS 
 The five elements of Directly Observed Therapy Short-Course, as outlined by the WHO, 
were expanded upon in 2000. The new expanded version of DOTS is called DOTS-plus, and it 
includes additional guidelines and suggestions when attempting to eliminate the presence of 
multidrug-resistant strains of tuberculosis. This revised version of DOTS should strengthen the 
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original DOTS program and improve it in a way that allows it to be applied to more patients 
suffering from tuberculosis infections (Grover & Takkar, 2008).  
 DOTS-plus includes five main pillars, like the original DOTS program, that structure its 
suggested approach to effectively dealing with MDR-TB cases. Two pillars of the DOTS-plus 
program directly overlap with the DOTS plan. These two pillars are that political commitment is 
a necessary component to address multidrug-resistant cases of tuberculosis, and that quality anti-
TB drugs should always be available to patients in need. The three pillars that are unique to the 
DOTS-plus program are proper drug susceptibility and culture testing to diagnose MDR-TB, the 
availability of the necessary amount of second-line drugs and other treatment strategies, and a 
recording system that keeps track of MDR-TB cases, how they are treated, and can report the 
treatment outcome. All of the pillars of the DOTS-plus program, even those that overlap with the 
original DOTS program, require a significant amount of financial resources and a fully 
operational DOTS program before DOTS-plus can be effective (Grover & Takkar, 2008). 
Therefore, implementing the DOTS-plus program is even more reliant on political commitment, 
specifically from a financial perspective, in order to work toward the goal of effectively treating 
all patients infected with tuberculosis. 
 
TREATMENT STRENGTHS AND LIMITATIONS 
 Tuberculosis can be treated in multiple different ways. All of the treatment methods 
currently used to treat tuberculosis are effective to some degree. However, despite their 
strengths, isolation, Directly Observed Therapy Short-Course, and Directly Observed Therapy all 
have limitations that make components of these methods ineffective, thus contributing to why 
people still stuffer from tuberculosis.  
39 
Isolation is a controversial, although widely used and recommended, method when 
considering various treatment options that are available to address tuberculosis infections. From 
one perspective, isolation can be seen as an effective and beneficial way to reduce the spread of 
tuberculosis. Isolation prevents contagious individuals suffering from active tuberculosis 
infections from interacting with their families and other members of their communities, thus 
eliminating the potential for transmitting the disease. Many prominent healthcare organizations 
recommend that patients undergo isolation when they are diagnosed with an active tuberculosis 
infection. Chapter 7, entitled “Tuberculosis Infection Control, ” of the CDC’s (2014g) booklet 
containing their recommended guidelines in addressing tuberculosis, states, “Persons who have 
or are suspected of having infectious TB disease should be placed in an area away from other 
patients, preferably in an airborne infection isolation (AII) room” (p. 197). An airborne infection 
isolation room houses one person and has an altered environment that discourages the 
transmission of tuberculosis (CDC, 2014g). Isolation is an effective and widely used strategy 
because it reduces the transmission of tuberculosis to other potential hosts by removing the 
patient from coming in contact with other individuals. 
 On the other hand, isolation has been shown to have significant emotional effects on 
patients that lived through the experience. Being taken away from family and friends to live 
alone while suffering from a potentially fatal disease and undergoing difficult drug regimens 
results in significant emotional distress. Mel Burden, an individual originally from the United 
Kingdom that contracted tuberculosis after working in a hospital located in rural South Africa, 
was isolated upon returning to the United Kingdom after living in South Africa. Ms. Burden 
explicitly stated the emotional turmoil she suffered while in isolation (Burden & Bakere, 2012). 
She describes the feeling of living in isolation:  
40 
I was very low, frustrated, and overwhelmingly lonely. I had only just started my new job 
 and already missed the companionship and the office banter. These feelings were made 
 worse by the complicated treatment and associated side effects. I felt extremely nauseous 
 and tired. (p. 2)  
Burden later discusses the difficulties in the treatment itself and mentions that these 
difficulties make defaulting from treatment an appealing option (Burden & Bakere, 2012). Based 
on these reflections, isolation seems to be a challenging and damaging treatment method for a 
patient suffering from tuberculosis. 
Isolation is usually required to be voluntarily chosen by the patient, but in specific cases a 
patient’s isolation can be involuntary.  Patients subjected to involuntary isolation are usually 
those that are contagious but adamantly refuse treatment even after being warned of the dangers 
of transmitting tuberculosis to others. There are multiple laws that must be followed and 
additional extenuating circumstances that must occur in order for involuntary isolation to be 
administered. These laws ensure the legality of subjecting a person to involuntary isolation. Also, 
extenuating circumstances ensure that this is the last resort and only used in the most desperate 
of situations. For example, an extenuating circumstance related to this issue could be when a 
patient is unable to take their own medication or if a patient refuses to take infection control 
measures despite the use of every possible way to reason with them (WHO, 2010). In these 
cases, an ethical tension arises between doing what is best for the patients and doing what is best 
for the community. According to Mel Burden’s testimony, isolation seems to be incredibly 
discouraging to the patient. However, subjecting a patient to isolation reduces the possibility that 
tuberculosis will spread throughout a community. Therefore, a difficult decision must be made to 
determine whether or not patients should undergo isolation.  
41 
In addition to the ethical concerns regarding isolation as an effective way to control 
tuberculosis, other recommended treatment options are surrounded by controversy as well. For 
example, Directly Observed Therapy Short-Course, as recommended by the WHO, is not 
effective in every community that uses it. Initially, the Directly Observed Therapy Short-Course 
program to address tuberculosis sounds like a program that would be incredibly effective at 
combatting tuberculosis. However, the program has many limitations. In 2001, 155 countries 
used the WHO’s DOTS program. The program is considered successful if greater than 85% of 
the patients enrolled in the program complete their treatment. However, countries using the 
DOTS program rarely reach this percentage. The number of patients that complete their 
tuberculosis drug regimens due to their enrollment in DOTS are variable because the program is 
not always implemented effectively. Many countries suffer from a lack of people able observe 
patients taking their medication, a lack of anti-tuberculosis drugs, not enough political 
commitment, as well as a number of other factors. In cases where DOTS is not implemented 
correctly, tuberculosis patients do not receive the benefits that the program has the potential of 
providing (Friedland et al., 2004). In these cases, the program could potentially do more harm 
than good to patients and communities by administering anti-tuberculosis medication to people 
without supporting them in their completion of the regimens. 
Despite many potential inconsistencies in the implementation of the DOTS program, 
there are some countries that have had success using the program. For example, DOTS programs 
have been successful in the Nyandeni district of South Africa’s Eastern Cape because of the 
inclusion of DOTS supporters. These supporters encourage patients as they participate in the 
DOTS program. Much of the success of this program can be contributed to the incentives present 
for individuals involved with the program. Motivating the workers observing patients taking 
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their medications is crucial. Additionally, providing support and encouragement for patients 
involved in DOTS is important. When all individuals involved with correctly implementing a 
DOTS program are motivated to continue to follow the program, the program is more successful 
(Dick et al., 2005). In this case in South Africa, adding DOTS supporters to the program 
increased motivation to participate in the program. Although this might not work in all cases, it 
could be a factor to consider if morale is low in DOTS programs implemented in other countries.  
Another country in which the DOTS program has been particularly successful is 
Bangladesh. In 1993, Bangladesh began to implement the DOTS program in a rural portion of 
the country. Sputum smears were performed on the patients enrolled in the study over the next 
two years. Of the new smear-positive patients in the study, 78% were cured of tuberculosis. After 
this promising cure rate had been realized, Bangladesh expanded its DOTS program to cover 67 
million people three years later. One of the unique factors that Bangladesh implemented when 
the country began the DOTS program was that the health care facilities and networks already in 
place around the country were used. The researchers reported that the “decentralization of 
sputum smear microscopy and treatment delivery services to peripheral health facilities” heavily 
influenced their success. Additionally, the researchers recommended that case monitoring and 
detection needs to be increased to continue to effectively cure tuberculosis cases (Kumaresan et 
al., 1998). Although these factors employed by the DOTS program in Bangladesh were 
successful in this cultural context, they might not be successful in all areas of the world. 
Therefore, these factors could potentially be used as helpful starting points in increasing the 
effectiveness of DOTS programs, but they should be altered when necessary depending on the 
cultural context in which DOTS is employed. 
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 The Directly Observed Therapy Short-Course program has many components, as 
previously mentioned. Specifically, the Directly Observed Therapy, or DOT, portion of the 
DOTS program suggested by the WHO is extremely controversial. The main strength of DOT is 
that it ensures that patients take their full drug regimen. When patients take their full regimen 
and take the drugs at proper times, the chance that the patient will develop a drug-resistant strain 
of tuberculosis decreases. Also, DOT ensures that the patient takes their drugs at the required 
times. When the patient follows the time schedule that specifies when they should take their 
medication, patients become non-contagious much quicker than if they were to take their 
medication intermittently. DOT is also an effective way of ensuring that the patient reacts well to 
their tuberculosis medication. Health care workers or the individuals designated to administer 
DOT monitor the patient for side effects and make sure that the patient is reacting well to the 
treatment (CDC, 2012c). Anyone that is approved by the patient to administer DOT can be, but 
analyzing the differences in the effectiveness of family members, co-workers, or medical 
professionals in providing DOT is beyond the scope of this paper.  
 According to the WHO, DOT is considered to be an ethical way to treat patients with 
active tuberculosis infections as long as the treatment remains patient-centered and a few 
concepts are kept in mind when implementing the program. To be considered an ethical 
approach to combating tuberculosis, DOT programs must reduce the costs that tuberculosis 
treatment has on patients, allow the patients to choose their observer, explain the consequences 
of discontinuing treatment, and properly manage the patients’ side effects. Additionally, the 
WHO requires that DOT programs, in order to be considered ethical, educate communities about 
tuberculosis disease and treatment to reduce the stigma associated with the disease (WHO, 
2010). The WHO (2010) states, “Directly observed therapy should be seen as a process for 
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providing support, motivation, and understanding to patients” (p. 16). DOT should be a patient-
centered approach to distributing tuberculosis medication.  
 In a study performed by Anuwatnonthakate et al. (2008), the effects of directly observed 
therapy on tuberculosis treatment were studied in four provinces in Thailand (p. 1). The 
researchers gathered epidemiological data from patients at hospitals in these four hospitals that 
had pulmonary tuberculosis, were never diagnosed with the disease before their current infection, 
and did not have a drug resistant strain of the disease. After administering DOT for two months, 
the effectiveness of the program was determined by the amount of patients that stopped their 
treatment. The researchers found that fewer patients defaulted from treatment when involved 
with the DOT program than those that were not (Anuwatnonthakate et al., 2008). When patients 
do not stop treatment and take it correctly, they are more likely to be cured from the disease 
quicker than those that do not. Therefore, DOT supported this agenda in Thailand. Thailand is 
not the only country in which DOT has reduced the amount of patients that stop tuberculosis 
treatment. Countries across the world that have employed DOT have realized decreased 
incidence of tuberculosis and a decrease in drug resistant strains (Friedland, 2004). 
 Although all of these strengths of DOT are compelling evidence that it should be 
implemented in most tuberculosis cases, there are significant limitations to the therapy that 
should cause medical professionals to think twice before employing this program. The 
limitations of DOT depend mainly on the way one considers a treatment method to be successful. 
In the Thailand example mentioned above, DOT could be considered effective because it 
reduced the amount of patients that defaulted from treatment. However, the paper did not 
mention whether or not DOT was perceived as a respectful way of treating patients suffering 
from tuberculosis. DOTs limitations are heavily rooted in patient perception of the program. 
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 DOTs could also be considered unsuccessful because the program could be interpreted as 
insulting to many patients. Telling a patient that they are unlikely to take their medication as they 
were told implies that the patient is irresponsible, possibly uneducated, and has other negative 
attributes that make them delinquent. Labeling an individual in this way is demeaning, and the 
entire DOT program is frequently seen as punitive (CDC, 2012c). 
 One compromise that could potentially foster respect for the patient as well as promote 
adherence to tuberculosis drug regimens is home-based directly observed therapy. As previously 
mentioned, fully analyzing the effectiveness of different individuals that can provide directory 
observed therapy is beyond the scope of this paper. However, recognizing the effectiveness of 
home-based directly observed therapy could provide a potential solution. The CDC mentions that 
family members are not the preferred people to serve as DOT volunteers for their family 
members (CDC, 2012c). However, based on a study performed in Botswana, patients that 
received directly observed therapy from family members did not exhibit significantly different 
cure rates from patients that received directly observed therapy from facilities (Kabongo & 
Mash, 2010).  According to Kabongo & Mash (2010), “HB-DOT is at least as good as FB-DOT 
in term of the treatment outcomes” (para. 5). Perhaps, if a patient is able to receive directly 
observed therapy from a family member, a patient might feel a sense of safety and respect even 
while someone watches them take their medication. HB-DOT eliminates the unfamiliarity 
between a patient and his or her DOT provider. Therefore, the situation might be more 
respectful. 
Overall, these results in Botswana are promising, and perhaps home-based directly 
observed therapy can be improved in order to be more effective in increasing the cure rates of 
tuberculosis while fostering respect for the patient. However, this treatment method might not 
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work all over the world. Not every patient in every cultural context will react the same way to a 
treatment method. Therefore, home-based directly observed therapy, and even directly observed 
therapy in general, might need to be culturally adjusted based on the context in which it is 
employed.  
 Despite the many strengths associated with currently methods used to treat tuberculosis, 
limitations still hinder these methods from being completely effective. Recognizing the 
limitations associated with tuberculosis treatment methods is the first step toward eliminating 
them. Promising case studies provide new concepts and additional factors that can potentially be 
applied to tuberculosis treatment programs in other communities so that tuberculosis can be 
fought efficiently and effectively. 
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Complications           
 Although the presence of treatment options and strategies to help countries fight 
tuberculosis seems promising, complications and additional factors make reducing the 
prevalence and incidence rates of the disease more difficult. Two major factors that influence 
patients suffering from tuberculosis are HIV/TB co-infections and the rise of drug resistant 
strains of tuberculosis. Both of these factors add new things to consider when discussing 
appropriate and effective treatment of tuberculosis. HIV/TB co-infections require different 
medications because the patient is suffering from two different diseases, and drug resistant 
strains of tuberculosis are not killed with the normal antibiotics used to eliminate tuberculosis. 
Therefore, analyzing these two complications to tuberculosis infection is important because they 
add caveats to consider when analyzing the presence of tuberculosis. 
 
HIV/TB CO-INFECTION 
 HIV and AIDS themselves are both major concerns around the world. However, the 
concerns associated with them are exponentially increased when considering tuberculosis in the 
context of HIV positive patients. Tuberculosis is the main infectious killer of patients suffering 
from HIV/AIDS (“TB & HIV/AIDS,” 2015). According to data from the WHO, patients with 
HIV are 26 and 31 times more likely to contract tuberculosis than others. Additionally, in 2013, 
1.1 million people of the nine million new cases of tuberculosis were infected with HIV 
previously to being diagnosed with tuberculosis (WHO, 2015f). These statistics reinforce the 
importance of addressing HIV/AIDS issues when considering tuberculosis.  Unfortunately, these 
two diseases are often present together even though both diseases are preventable and treatable. 
The graph below shows the percentage of patients infected with tuberculosis and HIV.  
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Figure 7. Percentage of tuberculosis (TB) patients with known HIV status by country, 2011. 
Adapted from the Global Tuberculosis Report, 2012, Retrieved November 12, 2014, from 
http://www.therapyceu.com/courses/386/tb-hiv-by-country-2011.jpg.	  
 
HIV and tuberculosis are so frequently found together because one disease allows the 
other to progress. When a patient is infected with HIV, they have a weakened immune system. 
This weakened immune system is due to a decrease in the number of T cells when an individual 
is HIV positive. T cells are one of two subtypes. They can be helper T cells that express the CD4 
ligand or killer T cells that express the CD8 ligand. HIV specifically targets T cells expressing 
the CD4 ligand, otherwise known as helper T cells. Both types of T cells are crucially important 
in killing pathogens that an individual’s immune system recognizes as foreign, but helper T cells 
are especially useful for initiating apoptosis. Apoptosis, or programmed cell death, will begin 
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when the host’s immune system recognizes and targets a cell that it wants to destroy (Alimonti et 
al., 2003). When HIV infects an individual’s body, it uses the host’s helper T cells as viral 
replication factories to continue to make more HIV virus. The virus kills the T cells in the 
process, by increasing the expression of DNA protein dependent kinases, DNA-PK. DNA-PK 
molecules signal for the CD4+ T cells to die (“NIH Scientists Discover How HIV Kills Immune 
Cells,” 2013). Therefore, as HIV progresses into AIDS in patients not receiving treatment, the 
patients have fewer T cells to attack the HIV virus and other infections that the individual may 
encounter.  
 In the context of tuberculosis, a lack of helper T cells and thereby a weakened immune 
system has especially dangerous consequences concerning patients with latent TB infections. As 
previously discussed, patients with latent tuberculosis do not suffer any symptoms from the 
infection because the bacteria is not spread through out their lungs and potentially other body 
parts. Instead, the host’s immune system uses macrophages and other immune cells to sequester 
M. tuberculosis in one region of the lungs forming a tubercle to keep the bacteria walled off from 
the rest of the body (Todar, 2012c). However, in patients with latent tuberculosis infections that 
are also infected with HIV, there are not enough immune cells present to keep M. tuberculosis 
trapped in tubercles. Therefore, latent tuberculosis can quickly become active tuberculosis, and 
M. tuberculosis spreads throughout the host’s body (Avert, 2015). 
 Many of the symptoms present in patients with HIV and TB co-infections are the same as 
those in patients with only active tuberculosis. These symptoms include coughing, chest pain, 
and fever. Unfortunately, patients suffering from HIV/TB co-infections frequently do not exhibit 
many of these classical TB symptoms or even any symptoms that usually signify a potential 
tuberculosis infection. Therefore, recognizing and diagnosing tuberculosis in HIV positive 
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patients can be challenging. In fact, it is even more challenging to diagnose tuberculosis in 
patients with HIV than patients without it. For example, approximately 20% of the chest X-rays 
performed on HIV positive patients that are suspected to have tuberculosis are negative for many 
of the usual indicators seen in X-rays of patients with tuberculosis. Additionally, HIV positive 
patients with tuberculosis also frequently test negative on sputum smear tests. The inaccuracy of 
chest X-rays and sputum smears in patients with HIV/TB co-infection makes it even more 
difficult to diagnose these cases. The inability to diagnose the co-infection quickly and correctly 
results in numerous cases that do not receive treatment in a timely manner or go completely 
unnoticed (TB Facts, n.d.-a).  
 Treating HIV/TB co-infections can be challenging because of the difficulties in mixing 
the drugs prescribed as the typical treatment for each disease. As previously mentioned, 
treatment for drug sensitive active tuberculosis infections is divided into the intensive phase and 
the continuation phase (CDC, 2012a). In HIV positive patients that also suffer from an active 
tuberculosis infection, it is recommended that the patient complete the initial phase by take 
isoniazid, a rifamycin, pyrazinamide, and ethambutol for two months followed by a continuation 
phase of isoniazid and a rifamycin for the last four moths. The dosages of these drugs and how 
often they are taken per week will be adjusted based on the severity of each patient’s HIV 
infection (CDC, 2014h). Regardless of the CD4+ T cell levels in patients suffering form HIV/TB 
co-infections, it is recommended that all patients begin antiretroviral treatment to stop the 
progression of HIV disease and suppress the virus itself. Usually, a patient infected with HIV 
and tuberculosis is recommended to begin their ARVs about two to eight weeks after beginning 
their anti-tuberculosis drugs (WHO, 2015g). Nucleoside/nucleotide reverse transcriptase 
inhibitors (NRTIs), non-nucleoside reverse transcriptase inhibitors (NNRTIs), protease inhibitors 
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(PIs), entry/fusion inhibitors, integrase inhibitors, and combinations of these treatments are all 
used as ways to stop HIV from replicating in an individual’s body (“Overview of HIV 
Treatments,” 2009).  
 Unfortunately, there are many potentially disastrous side effects that can result from 
taking tuberculosis medications and ARVs at the same time. These side effects include 
hepatotoxicity, severe skin reactions, and other more serious concerns. One of these dangerous 
issues is tuberculosis immune reconstitution syndrome, or TB IRIS. TB IRIS is a specific 
condition that occurs in an individual suffering from tuberculosis when their immune system 
partially recovers and causes an exaggerated inflammatory response to infectious particles (TB 
Facts, n.d.-a). I realize that there are many other dangerous side effects with mixing anti-
tuberculosis drugs and ARVs, but discussing those and their treatment implications is beyond the 
scope of this paper. 
 One of the main concerns regarding HIV/TB co-infections is that patients suffering from 
these diseases are frequently diagnosed with having multi-drug resistant strains of tuberculosis. 
Therefore, this relationship led many people to believe that somehow HIV/TB co-infection can 
increase the mutation of the tuberculosis bacteria to cause new drug resistant strains. However, 
studies have shown that this is not necessarily the case. There are many associated factors 
between HIV and multi-drug resistant tuberculosis, such as shared risk factors that promote 
transmission of both diseases, that seem to make these two issues more epidemiologically related 
than they actually are (Suchindran et al., 2009). Despite the fact that one disease does not 
directly cause the other, the acknowledgement that HIV positive patients are frequently infected 
with multi-drug resistant strains of tuberculosis is important to consider in order to correctly treat 
a patient suffering from tuberculosis. 
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TREATMENT CONCERNS 
 Treatment of HIV and tuberculosis co-infections provides a great challenge to the 
healthcare systems established in many countries. Specifically, effective coordination of drug 
intervention is important in addressing HIV and tuberculosis co-infections with success. Early 
detection of HIV infection and tuberculosis infection sets the stage for additional effective 
treatment methods and programs to be employed. The goal in treating tuberculosis and HIV co-
infection is to promote effective tuberculosis and HIV treatment while eliminating the negative 
effects these treatments have on each other.  
 Unfortunately, there are many challenges associated with effectively addressing HIV/TB 
co-infections. One of the major challenges, as was mentioned previously, is managing the drug 
toxicities associated with anti-tuberculosis drugs as well as antiretroviral drugs. Drug toxicity 
can be an issue when both rifamycins, such as rifampin, are prescribed with some antiretroviral 
agents. Modification in either of these regimens may be recommended depending on what drugs 
are prescribed to the individual in order to maximize the efficacy of both treatments. A major 
concern associated with drug toxicities is the potential that a patient could develop 
hepatotoxicity, or liver damage from drugs used to address tuberculosis or HIV infections. 
Therefore, resources need to be appropriately allocated to ensure that patients are monitored for 
this potential side effect. In order to decrease the risk of potential side effects associated with 
drug toxicity, public health systems must coordinate with physicians, patients, and clinics and 
facilities to ensure that patients are safely and effectively treated for HIV/TB co-infection 
(AIDSinfo, 2015). 
The WHO outlines many recommendations associated with treating tuberculosis and HIV 
co-infections. One of the main recommendations the WHO provides is that countries should 
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follow the “Three I’s” for HIV/TB co-infection treatment and containment. The first “I” 
represents intensified TB case finding. Many people that test positive for HIV and receive 
antiretroviral drugs still die of undiagnosed tuberculosis. Therefore, implementing a way to 
effectively recognize and diagnose tuberculosis in patients that are HIV positive is important 
(WHO, 2015h). The second “I,” which stands for isoniazid preventive therapy (IPT), encourages 
the prescription of isoniazid to patients suffering from tuberculosis and HIV co-infections 
because it does not negatively interact with antiretroviral drugs like rifamycins do (WHO, 
2015i). The third “I,” infection control, involves administrative, environmental, and individual 
ways to reduce the transmission of tuberculosis in populations vulnerable to contracting it. Some 
potential ways to reduce the transmission of tuberculosis are the formation of an effective triage 
system to diagnose patients and connect them with the proper medical professionals, improve 
ventilation in rooms, provide sufficient protective equipment for individuals working with 
patients suffering from this co-infection, and encourage patients the proper cough etiquette 
WHO, 2015j).  
Following the three “I’s” and the WHO’s recommendations for addressing TB/HIV co-
infections are very labor and resource intensive. The significant resource requirements to treat 
TB/HIV co-infections refers back to the WHO’s DOTS program, which is still implemented in 
areas suffering from high burdens of HIV/TB co-infection. Political support and involvement, a 
component of DOTS, might be even more necessary in HIV/TB co-infection treatment so that 
sufficient resources are available (Steinbrook, 2007). 
Ideally, all of these factors would be followed correctly and would be effective in all 
cases. However, in order for the three “I’s” to be the most effective at addressing HIV/TB co-
infections, they need to be adapted and potentially altered when necessary. One country that 
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altered the three “I’s” to meet its citizens’ needs was South Africa. In South Africa, isoniazid 
preventive therapy has included that tuberculin skin testing, TST, opportunities need to be 
available to patients that need it after realizing the benefits of TST in some local communities 
(WHO, 2015i), South Africa’s adaptation of isoniazid preventive therapy is a perfect example of 
how the WHO’s recommendations will be most effective if they are altered based on the context 
in which they are operating. Even though the benefits of tuberculin skin testing were seen in 
South Africa, this does not mean that an increase in tuberculin skin testing should be applied to 
programs all over the world that address HIV/TB co-infection. Therefore, an effective way to 
treat HIV/TB co-infections would most likely be one that builds off current effective 
recommendations while uniquely altering them to the needs of the community in which they are 
being applied. 
  
 
DRUG RESISTANT TUBERCULOSIS 
 
 The second major complication that arises regarding tuberculosis treatment is that not all 
M. tuberculosis infections respond to the drug regimens that are prescribed to kill them. As 
previously discussed, many effective drugs are available to treat patients suffering from both 
latent and active tuberculosis infections. Unfortunately, they are not effective in all patients 
suffering from TB disease. These strains of tuberculosis are called multidrug-resistant or 
extensively drug resistant. Multidrug-resistant tuberculosis, or MDR-TB, is incredibly difficult to 
kill. In some cases, nothing can be done for patients suffering from drug resistant strains of the 
disease. To be classified as multidrug-resistant, the tuberculosis strain infecting an individual 
must be resistant to at least isoniazid and rifampin, which are the two strongest tuberculosis 
drugs available (CDC, 2012d). Five percent of all TB cases in 2013, an estimated 480,000 
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people, developed multidrug resistant tuberculosis. Only 48% of these people survived the 
disease. One of the driving factors behind these dismal statistics is the inability to diagnose 
patients with multi-drug resistant strains of tuberculosis in a timely manner. If all TB positive 
patients had been tested for multidrug-resistant strains of the bacteria, 300,000 MDR TB cases 
could have been detected and potentially received appropriate treatment sooner (WHO, 2014). 
The figure below shows the number of multi-drug resistant strains of tuberculosis around the 
world in 2013.  
 
Figure 8. Notified MDR-TB Cases (Absolute Numbers), 2013, Adapted from the Global Health 
Observatory (GHO) Data, n.d., Retrieved November 12, 2014, from http://www.who.int/gho/tb/ 
drug_resistant/en/. Copyright 2015 by the WHO. 
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Multidrug-resistant tuberculosis is spread through infectious bacteria traveling from one 
host to another through the air in the same way that tuberculosis strains that are sensitive to drug 
interventions spread. Additionally, the symptoms of MDR TB are the same as non-resistant 
tuberculosis (CDC, 2014i).  However, there is an additional step taken when diagnosing a patient 
with a drug resistant strain of tuberculosis. A drug susceptibility test, or DST, is performed in 
order to determine what drugs an individual’s strain of tuberculosis is sensitive to or to ensure 
that the patient’s tuberculosis infection is drug resistant. A DST can be either phenotypic or 
genotypic. A phenotypic DST is either direct, inoculating one set of media containing drugs and 
one set of media without drugs with tuberculosis bacteria, or indirect, inoculating media 
containing tuberculosis drugs with a pure culture of tuberculosis bacteria. In both cases, the way 
that the cultures grow on the media is observed. If the culture grows on media containing drugs, 
then the bacteria are drug resistant. Genotypic drug susceptibility tests, the alternative to indirect 
or direct phenotypic drug tests, are preformed to identify exactly what mutation occurred in the 
bacteria for it to become resistant to specific drugs (TB Facts, n.d.-b). Despite the addition of a 
DST to series of tests used to diagnose a patient with tuberculosis, the only major difference drug 
sensitive tuberculosis infections and multidrug-resistant strains of tuberculosis is their responses 
to tuberculosis drugs.  
Presentation of multidrug-resistant tuberculosis is slightly different in children than it is 
in adults. Where adults present with characteristic symptoms of the disease such as a persistent 
cough and significant weight loss, children do not present with these classic symptoms. Usually, 
their symptoms are less specific making tuberculosis cases in children much more difficult to 
diagnose. Additionally, children with tuberculosis normally have a lower load of tuberculosis 
bacteria in their bodies than adults do, so cases of children’s tuberculosis are frequently missed. 
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Unfortunately, 30,000 children a year suffer from drug resistant strains of tuberculosis. Despite 
this large number of children suffering from these strains of tuberculosis, children are usually not 
a priority in diagnosing and treating drug resistant tuberculosis because they are less infectious 
than adults. However, the infection usually progresses more quickly in children than adults so 
children die of tuberculosis without even being diagnosed (Partners In Health, 2014).  
 There are many reasons that can cause a strain of tuberculosis to become resistant to 
drugs. The CDC mentions that drug resistance can be caused my improper drug prescriptions by 
the medical professional tending to the patient, an insufficient supply of drugs, or the usage of 
poor quality drugs. One of the most controversial ways that drug-resistance develops is through 
patients who do not complete their full-course of mediation and are therefore characterized as 
non-compliant patients (CDC, 2014i). Specifically, patients that do not take their prescribed TB 
drugs when they should, or do not take the required dose of these medicines catalyze the creation 
of tuberculosis bacteria that will be resistant to the drugs the patient took (WHO, 2015k). By 
inappropriately taking medication, the tuberculosis bacteria undergo genetic mutations that allow 
them to survive once introduced to the drugs again (Grover & Takkar, 2008). Non-compliant 
patients are usually in areas of the world where tuberculosis treatment facilities are weak and 
lack a significant amount of resources (WHO, 2015k).  
 MDR-TB is a terrifying form of tuberculosis to be infected with but there is still one 
other form that causes even more concern. Extensively drug resistant tuberculosis is resistant to 
most of the extremely strong tuberculosis drugs including isoniazid, rifampin, any 
fluoroquinolone and at least one second-line injected drug. Because of its lack of response to 
many of the drugs usually used to treat tuberculosis, patients with extensively resistant 
tuberculosis do not have many other effective treatment options (CDC, 2012d). 
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TREATMENT CONCERNS 
 Multidrug-resistant strains of tuberculosis cause significant treatment concerns due to 
their contagious nature, like normal tuberculosis, and their difficulty to cure. MDR-TB strains 
are present all over the world, so successfully treating these cases is crucial in taking steps 
toward ridding the world of tuberculosis. One of the major obstacles to treating drug resistant 
strains of tuberculosis effectively is diagnosing the disease in a timely manner. As previously 
mentioned, drug susceptibility tests are preformed to determine whether or not a patient’s strain 
of tuberculosis is susceptible to drugs and what drugs, if any, the bacteria are susceptible to. 
Unfortunately, drug susceptibility tests are either incredibly time consuming or expensive to 
perform (TB Facts, n.d.–b).  
Indirect phenotypic drug susceptibility tests are particularly time consuming. 
Tuberculosis bacterial cultures must first be grown in the lab after scientists receive a sample 
from a patient. Culturing tuberculosis bacteria takes, on average, about four weeks to get a test 
result. Then, the culture is used in either direct or indirect phenotypic tests. It takes another four 
to six weeks after beginning a direct or indirect phenotypic drug susceptibility test to determine 
the results. The main problem with DST’s taking so long is that the patient needs to begin 
treatment as soon as possible after being diagnosed with tuberculosis. Therefore, the longer it 
takes to determine what drugs, if any, a patient’s strain of tuberculosis is sensitive to the longer it 
takes for a patient to begin treatment. One way to speed up the DST process is to use machines 
that use liquid media instead of solid media to determine drug susceptibility (TB Facts, n.d.-b).  
 These machines and those used to perform genotypic drug susceptibility tests are 
expensive. Therefore, not only is a significant amount of time required to perform drug 
susceptibility tests when diagnosing cases of drug resistant tuberculosis. Enough money to buy 
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these complex machines is also necessary and can be another obstacle in diagnosing drug 
resistant strains of tuberculosis in a timely manner. An insufficient amount of trained individuals 
that are able to operate these complex machines as well as a lack of financial resources to buy the 
machines in the first place both result in barriers to treatment of drug resistant strains of 
tuberculosis (TB Facts, n.d.-b). 
 Another public health concern related to drug resistant strains of tuberculosis is that 
children suffering from these strains go unnoticed. Children are less infectious than adults, 
frequently die of these strains without being properly diagnosed, and have lower loads of the 
bacteria in their bodies so their infections are difficult to detect. For these reasons and many 
more, children are not receiving enough medical attention in relation to their tuberculosis 
infections (Partners in Health, 2014). 
 Dr. Mercedes Becerra is a major player in addressing children’s MDR-TB. Dr. Becerra 
works at Partners in Health as a tuberculosis specialist and as an associate professor at Harvard 
Medical School. She and her colleagues published an article that discusses children’s multidrug 
resistant strains of tuberculosis and attempts to determine how many children in the world suffer 
from MDR-TB. Dr. Becerra states that discovering drug-resistant cases in children highlights 
that transmission has not been stopped, and a child did not receive treatment (Partners in Health, 
2014). To respond to this issue and make the global community aware of the significant amount 
of children suffering from multidrug resistant tuberculosis, Dr. Becerra and Dr. Soumya 
Swaminathan, the head of India’s National Institute for Research in Tuberculosis, formed the 
Sentinel Project in 2011 (Partners in Health, 2014). The Sentinel Project’s goal is to increase 
access to effective treatment methods for children suffering from multidrug resistant strains 
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tuberculosis by reaching out to its international network of individuals that share this vision 
(Sentinel Project, n. d.).  
 Dr. Becerra mentions that an important step that needs to be in order to address 
tuberculosis infection in children is to implement contact tracing to identify people children have 
come in contact with. This will allow researchers and medical professionals to quickly determine 
how the child contracted the disease as well as other potential cases so that treatment can be 
administered as soon as possible. Dr. Becerra is currently working on increasing the amount of 
contact tracing used around the world. Ideally, this will eventually translate into recognizing 
children suffering from drug resistant strains of tuberculosis instead. Eventually, as a result of 
this recognition, fewer children will die from this preventable disease (Partners in Health, 2014). 
Children are not the only ones suffering from multidrug-resistant strains of tuberculosis. 
Significant treatment concerns regarding how MDR-TB is addressed in adults are present all 
over the world. A country with one of the highest burdens of drug resistant strains of tuberculosis 
is Russia. Partners in Health has battled multidrug resistant tuberculosis in Russia since 1998 and 
a particularly beneficial initiative, the Sputnik Initiative, provides a variety of suggestions that 
could potentially be adopted by other countries around the world. Sputnik provides tuberculosis 
treatment every day to patients that are at a high risk of discontinuing their treatment. These 
patients are usually people that have been forced to leave hospitals due to behavioral problems, 
those that abuse substances, and people with socioeconomic struggles. The Sputnik Initiative 
shows the global community that patients from backgrounds that label them as unable to adhere 
to tuberculosis treatments can successfully complete tuberculosis treatments, and that a patient-
centered approach to tuberculosis treatment outside of a hospital is an effective way to treat 
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tuberculosis. According to the PIH website, since its implementation, the Sputnik Initiative has 
had a treatment success rate of 71.1% (Keshavjee et al., 2014).  
 Both the Sentinel Project and Sputnik Initiative provide beneficial suggestions for how to 
best address multidrug resistance. Raising awareness of these strains and providing support for 
patients battling these types of tuberculosis have been effective in both of these instances. 
Perhaps, these concepts can be transferred to other areas of the world suffering from high 
burdens of multidrug-resistant tuberculosis in order to make treatment methods for multidrug-
resistant strains of tuberculosis more effective. 
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Perceptions of Tuberculosis         
As previously discussed, tuberculosis has plagued humans for centuries. Treatments 
improved as time progressed, drug resistant strains incurred additional damages to infected 
individuals, and the prevalence of HIV co-infection has added a new dimension to considering 
tuberculosis. However, these background facts and statistics provide only one lens through which 
to understand tuberculosis and those that it infects. Sontag (1989) writes, “My point is that 
illness is not a metaphor, and that the most truthful way of regarding illness – and the healthiest 
way of being ill – is one most purified of, most resistant to, metaphoric thinking” (p. 3). In other 
words, Sontag highlights the importance of considering the way that people, those infected and 
uninfected with it, perceive a disease.  Not only does tuberculosis physically damage an 
individual’s body, tuberculosis metaphorically damages its victims by subjecting infected 
individuals to the various stigmas associated with the disease. This is referred to as the hidden 
burden of the disease (Somma et al., 2008). Applying Sontag’s suggestion, it is important to 
consider how people perceive tuberculosis and the stigmas associated with it, or what it is a 
metaphor for, when attempting to understand the disease and its implications. 
Stigmas and perceptions arise in response to a variety of different factors. They are 
created when an individual behaves in a way that is not what society expects or has a unique trait 
or characteristic that sets them apart. Whatever these unique behaviors or characteristics are that 
an individual possesses, society interprets them negatively. Instead of being ways that an 
individual expresses his or her individuality, they become the source of ridicule or the catalyst 
for the devaluing of an individual (Dodor et al., 2008). In the context of tuberculosis, stigmas 
associated with the disease are created by infected individuals’ perceptions of themselves as well 
as the perceptions that unaffected community members have of people suffering from 
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tuberculosis. These perceptions and the stigma created by the perceptions that surround 
tuberculosis have a profound impact on individuals suffering from the disease. The perceptions 
effect treatment methods, the mental health of tuberculosis patients, and cohesion within a 
community in general. Since tuberculosis infects individuals all over the world, there are 
similarities and differences between the ways the disease is perceived. These perceptions 
establish tuberculosis as a metaphor (Sontag, 1989). 
 Both cross culturally and internationally, tuberculosis is a metaphor for isolation. 
Isolation due to the presence of active tuberculosis infection presents itself in many forms. 
Patients infected with tuberculosis feel isolated from their families, their communities as a 
whole, and even themselves. Interestingly, tuberculosis as a metaphor for isolation is also evident 
in the way the causal bacteria infect a host’s body. Examining each of these different forms of 
isolation provides beneficial insight into how perceptions of tuberculosis impact the people 
suffering from it, the communities they live in, and how best to address the disease. 
 
BACTERIAL ISOLATION 
 Tuberculosis’s use as a metaphor for isolation begins at the microscopic level. As 
previously mentioned, individuals can suffer from latent and active forms of the disease. The 
active form of tuberculosis infection involves the spreading of M. tuberculosis throughout the 
patient’s body. The bacterial infection usually begins in the lungs, but can spread to other regions 
including the spine, lymph nodes, and brain as the infection progresses and especially if it is left 
untreated (Wiwatworapan & Anantasetagoon, 2008). A patient suffering from an active M. 
tuberculosis infection usually presents with symptoms characteristic of TB infection, such as 
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coughing, fever, and weight loss, and potentially with additional symptoms based on whether or 
not the bacteria spread and what region of the body they infected (WHO, 2015l). 
On the other hand, characteristics of the latent form of tuberculosis infection are the 
opposite of those related to active tuberculosis infection. Patients with latent tuberculosis 
infections do not show any of the characteristic symptoms. It is even possible for an individual to 
be unaware that they have a latent tuberculosis infection. In addition to the absence versus 
presence of symptoms, latent tuberculosis differs from active tuberculosis because the bacteria 
do not spread in individuals with latent infections. Instead, the bacteria are sequestered in 
tubercles within the patient’s lungs. Tubercles are hardened nodules in the lungs containing 
macrophages infected with M. tuberculosis. The body forms these tubercles once it realizes that 
it cannot eliminate the infection. Therefore, its alternate option is to wall of a region of the lungs 
where the bacteria are concentrated. In other words, the body isolates the bacteria from the 
surrounding tissue (Müller, 2011).  
The physical isolation of M. tuberculosis by the host’s body when suffering from a latent 
infection is analogous to the other forms of isolation that an individual with active tuberculosis 
undergoes. Just like the host’s body isolates M. tuberculosis from the rest of the lungs and 
surrounding tissue, patients with active forms of tuberculosis are isolated from their families and 
communities, and even suffer a more personal self-isolation. Unfortunately, these forms of 
isolation can be more emotionally and mentally damaging to the patient suffering from active 
tuberculosis disease, and they have serious implications when considering treatment efficiency 
and efficacy. 
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ISOLATION FROM THE COMMUNITY 
 Beyond considering the actions of M. tuberculosis on the microscopic level, the isolation 
associated with tuberculosis infection affects human interaction in detrimental ways. 
Tuberculosis as a metaphor for isolation is especially evident when considering the separation 
between infected individuals and the communities they live in. Unfortunately, individuals 
suffering from tuberculosis all over the world and from different time periods feel or have felt 
separated from their communities.  
In the nineteenth and twentieth centuries, the tuberculosis’s metaphor for isolation was 
employed by individuals looking to distinguish themselves from the lower class people of the 
time. People were no longer born into a social class. Instead, each individual asserted his or her 
own social status. In other words, people had to isolate themselves from lower levels of society 
in order to distinguish themselves as members of the upper class. This intentional isolation was 
especially applicable to women living in the nineteenth century. A new ideal of what the 
fashionable woman looked like was intimately intertwined with establishing ones self as upper 
class. It was trendy for women of the upper class to be gaunt. These women no longer hungrily 
ate their meals, but rather picked at them delicately (Sontag, p. 28).  
Tuberculosis fits into this motif perfectly. The disease causes a loss in appetite and 
physical wasting away of the body, both of which resulted in the bodily image that was so 
desirable to women of the day. Susan Sontag (1989) mentions that during the nineteenth and 
twentieth centuries, “It was glamorous to look sickly” (p. 28). Additionally, long spells of 
coughing, as is common in individuals with active tuberculosis disease, were considered chic. 
Women suffering from this disease had no qualms about discussing these coughing spells with 
others. For example, Marie Bashkirtsev, a Ukrainian writer and painter, suffered from 
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tuberculosis (Kuipue, 2014). She explicitly discussed one of her coughing spells in her Journal 
in 1887 (Sontag, p. 29). She describes her coughing fit, “But for a wonder far from making me 
look ugly, this gives me an air of languor that is very becoming” (as cited in Sontag, 1989). 
Active tuberculosis infections helped women achieve the fashionable image of the time and 
assisted them in isolating themselves from society’s lower classes. 
During this time period, women were not the only ones who actively used tuberculosis as 
a way of isolating themselves from lower societal classes. Creative geniuses of the time did this 
as well. Many artists, poets, and novelists living in the nineteenth and twentieth centuries were 
infected with tuberculosis. Famous people who suffered from tuberculosis include Percy B. 
Shelley, John Keats, and Franz Kafka (Sontag, 1989). Over time, tuberculosis came to be seen as 
a disease that specifically infected people who were artistic, passionate, romantic and interesting. 
Susan Sontag (1989) asserts, “The melancholy character – or the tubercular – was a superior one: 
sensitive, creative, and being apart” (p. 32). In fact, contracting the disease was even twisted, 
albeit possibly jokingly, into a complement. Shelley is quoted writing to Keats about their 
tuberculosis infections and saying, “this consumption is a disease particularly fond of people 
who write such good verses as you have done…” (as cited in Sontag, 1989). By associating 
active tuberculosis disease with famous and successful creative figures, tuberculosis gradually 
became a metaphor for establishing creative minds as superior ones, thus isolating them from 
individuals who were not creative and therefore not worthy of being infected by the disease. 
Along with tuberculosis’s association with isolating the creative minds of the nineteenth 
and twentieth centuries, the disease gave famous artists and writers a stereotypical image similar 
to the fashionable women of the time. In fact, Sontag quotes Théophile Gautier, a French poet 
and novelist, supporting this image (“Théophile Gautier,” 2014). He said, “When I was young, I 
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could not have accepted as a lyrical poet anyone weighing more than ninety pounds” (as cited in 
Sontag, 1989). These famous creative identities were thin, wiry, and sickly, which once again 
aligns with the effects that tuberculosis has on its host’s body. Tuberculosis isolated the creative 
geniuses of the time from the other members of the society by creating a stereotypical image in 
them that many others desired and attempted to attain. Unfortunately, since this stereotype was 
interwoven with a deadly disease, many artists, poets, and other writers ascribing to this image 
died at tragically young ages due to tuberculosis (Sontag, 1989). 
Tuberculosis did not only affect the physical images of men, women, and creative 
figureheads of the nineteenth and twentieth centuries. Often, a geographical isolation became 
part and parcel of being a notable member of society infected with tuberculosis. Many famous 
individuals suffering from tuberculosis isolated themselves from society even further by going 
into exile. They traveled all around the world to reach the prime exilic location that they thought 
would heal them of their illness. Places such as Italy, the Mediterranean, the South Pacific, and 
the desert were all locations to which famous tuberculosis sufferers exiled them selves by their 
own will or after being advised to do so by a physician. Susan Sontag (1989) says, “The TB 
sufferer was a dropout, a wanderer in endless search of a healthy place” (p. 33). John Keats, 
Frédéric Chopin, Robert Louis Stevenson and D.H. Lawrence were all among those that ascribed 
to tuberculosis’s metaphor for isolation and went into exile to become cured of the disease 
(Sontag, 1989). Unfortunately, none of these famous figures were cured of their tuberculosis 
infections. 
Currently, the metaphor for tuberculosis representing isolation remains applicable all 
over the world. Specifically, individuals in the United States, Ghana, South Africa, Bangladesh, 
and Malawi report feeling isolated from their communities for a variety of reasons directly 
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resultant of active tuberculosis infection. Isolation from the community manifests itself in 
various forms in different areas of the world. Despite these differences, it is crucial to recognize 
that regardless of what cultural context the disease operates in or where the person infected with 
it lives, patients suffer significant feelings of isolation from their communities that directly affect 
diagnosis and treatment of the disease.  
 One manifestation of patients’ isolation from their communities is the fear of job loss 
and financial insecurity that presents itself in many males with active tuberculosis. Somma et al. 
(2008) describe these feelings in men suffering from active tuberculosis in Lilongwe, the capital 
of Malawi, and ten rural sub-districts of Bangladesh (p. 860). The researchers gave Semi-
structured Explanatory Model Interview Catalogue interviews to 100 people at their data 
collection sites to assess a variety of factors regarding tuberculosis. However, they interviewed 
individual people to determine stigma. The researchers found that, in Malawi, when men are 
diagnosed with an active tuberculosis infection they are frequently unable to keep their jobs. 
These men are employed as skilled or unskilled laborers and provide for their families with the 
money they earn working at these jobs. Men with active tuberculosis were not allowed to 
continue working at their jobs and were also unable to return to those jobs once they began 
treatment. These men were even unable to return to their jobs after being completely cured of the 
disease. The researchers quoted one patient that said, “I was asked to stay away form work. I 
have been dismissed from work due to the illness. I would not be allowed to continue working 
with my employers after I finish the treatment” (as cited in Somma et al., 2008). Therefore, men 
living with active tuberculosis infections in Malawi feel a significant amount of isolation from 
their communities by suffering from job insecurity and by extension financial insecurity unlike 
the healthy men in Lilongwe (Somma et al., 2008).  
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In rural areas of Bangladesh, men infected with tuberculosis share a similar sentiment to 
patients in Lilongwe. These patients felt a significant amount of fear related to being unable to 
work due to tuberculosis infection. When an individual is infected with tuberculosis, he or she 
gradually becomes weaker due to the body’s physical wasting. Therefore, weakness in men 
suffering from tuberculosis in Bangladesh makes it incredibly difficult for them to work as 
efficiently as their healthy counter-parts. In some cases, weakness prevents these men from 
working at all. Being unable to work results in being unable to provide for one’s family. In 
Bangladesh, if a man cannot provide for his family, he must borrow from neighboring families in 
order to save his own. This action is heavily stigmatized (Somma et al., 2008). One patient 
mentioned, “We had to borrow because there is a crisis in our family. People did not say 
anything in from of my face after I got this disease, but they have said things in my absence” (as 
cited in Somma et al., 2008). 
In a different study, a different manifestation of tuberculosis as a metaphor for isolation 
as noticed in Ghana. According to these researchers, many tuberculosis patients feel isolated to 
some degree by their communities because members of the community shame them for being 
infected with the disease. Dodor et al. (2008) conducted individual interviews and hosted focus 
groups with tuberculosis patients in the Shama Ahanta East Metropolitan District (p. 1048). 
Through their conversations, the researchers realized that many patients felt isolated from their 
communities because many people believed that contracting tuberculosis was the result of 
engaging in risky behaviors that the community deemed as inappropriate. These risky behaviors 
included smoking cigarettes and cannabis, drinking alcohol, and using hard drugs. Sharing these 
substances or the materials with which they are consumed or injected into the body with 
someone infected with tuberculosis was considered to be a way that tuberculosis is spread. 
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Additionally, members of the community believed that individuals with tuberculosis actively 
tried to spread the disease to others. It was expected by community members that tuberculosis 
patients isolate themselves in order to protect the community. If patients with tuberculosis do not 
isolate themselves, cough in public, or dispose of their sputum in anything other than a container 
that they keep on their person, it is interpreted as an intentional attempt to infect others with 
tuberculosis (Dodor et al., 2008). Therefore, suffering from tuberculosis in Ghana’s Shama 
Ahanta East Metropolitan District represents isolation from the community because it incurs 
behavioral expectations that separate tuberculosis patients from healthy individuals living in the 
community. 
Patients in this region of Ghana not only felt isolated from the community they live in as 
a whole but also specifically from the medical community. According to Dodor et al. (2008), 
“Certain practices of health staff were pointed out as making TB shameful and enhanced the fear 
of the disease” (p. 1050). The researchers discovered that community members thought doctors 
gave tuberculosis strange names. This concept combined with the physical separation of 
tuberculosis patients from other patients at the hospital caused tuberculosis sufferers to feel 
isolated from the medical community. Additionally, specific protective measures that health care 
professionals took around tuberculosis patients caused them to feel isolated from the medical 
community. For example, wearing gloves and masks around patients with tuberculosis made the 
patients feel uncomfortable. Tuberculosis patients interpreted these protective measures as 
meaning that individuals suffering from tuberculosis are not allowed to be in public or around 
individuals who are not infected with the disease. This interpretation even extended to patients 
that died of tuberculosis infection. One male participating in a focus group noted that the bodies 
of people killed by tuberculosis cannot be taken to the respective patients’ homes. Instead, health 
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professionals performed post-mortem bodily preparation in the hospital, and then the bodies are 
taken directly to the cemetery. Therefore, these perceptions of tuberculosis as representing 
isolation result in tuberculosis patients feeling separated from their community (Dodor et al., 
2008). 
In all three cases mentioned above, active tuberculosis infections cause individuals to feel 
separated from their communities, thus further supporting the concept that tuberculosis is a 
metaphor for isolation. Additionally, in all of these cases, patients reported that the negative 
perceptions that their community members had of tuberculosis affected their attempts to seek 
medical attention regarding their disease. Perhaps if the stigma associated with tuberculosis as 
well as the metaphor for isolation surrounding the disease were debunked, more people would 
feel comfortable seeking medical attention. If this became the case, ideally more individuals 
would be diagnosed with the disease before it has significantly progressed. The elimination of 
stigma and the negative perception of tuberculosis might also benefit treatment methods. If 
patients felt more comfortable visiting medical clinics to receive their medication, perhaps more 
patients would successfully complete their drug regimens and be cured of tuberculosis. 
 
ISOLATION FROM FAMILY 
Tuberculosis’s metaphor for isolation that is present on the community level also affects 
the main subunit with which communities are built, the family. Tuberculosis and its effects on 
family life are especially relevant to women living in Bangladesh, India, Malawi, and Colombia 
(Somma et al., 2008). Despite the differences in the level of stigmatization associated with 
tuberculosis in various geographic regions, it is crucial to understand that women feel isolated 
from their families due to tuberculosis and its stigma. Addressing tuberculosis as a metaphor for 
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isolation in relation to the separation between women and their families could potentially 
positively influence treatment interventions and hopefully result in more women being cured of 
the disease. 
Although the cases mentioned above are current examples of the isolation felt between 
women infected with tuberculosis and their families, women have felt this isolation for decades. 
In my great-oma’s case, the isolation associated with tuberculosis is evident in the way that my 
oma talks about the disease to this day, specifically related to the way that tuberculosis and its 
metaphor for isolation affected their family. When she was diagnosed, Suzanne Bitner was 
isolated from the rest of the Bitner family by being admitted into a sanitarium. Her admittance 
into the sanitarium resulted in a physical isolation from the family, but the longer she stayed 
away the more isolated my oma felt from her. The rest of the Bitner family members’ lives had 
to adjust with my great-oma living somewhere else. Suzanne Bitner no longer raised her own 
daughter. Instead, my oma’s grandmother became her primary female authority. In turn, the 
isolation became gradually more psychological as well as physical. The feeling of isolation was 
only intensified when my great-oma was moved to the storage room in a nearby farmer’s field 
for the last few months of her life. Despite being in better surroundings than the sanitarium, 
Suzanne Bitner remained isolated from interacting with her family due to her tuberculosis 
infection until she passed away. 
Unfortunately, women living in the late twentieth and early twenty-first centuries still 
suffer isolation from their families due to tuberculosis infection. D. Somma et al. (2008) explore 
the gender-specific perceptions and stigma associated with active tuberculosis infections (p. 
856). Interestingly, there are many similarities between the isolation felt by women suffering 
from tuberculosis in Chennai, India and Lilongwe, Malawi. In both of these countries, women 
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rely heavily on their husbands for support and protection. Therefore, a woman’s marriage 
prospects are incredibly important. Suffering from tuberculosis is not something that potential 
husbands or their families value highly in a potential wife or daughter-in-law. As a result, 
women with tuberculosis disease in these two countries are concerned about their reputations as 
suitable wives, which will eventually determine whether or not they will marry (Somma et al., 
2008). In turn, they feel isolated from the other healthy women also seeking potential husbands 
and therefore their future  
The concerns mentioned above apply specifically to women suffering from tuberculosis 
before they are married, but if a woman is infected with tuberculosis after marrying the isolation 
associated with tuberculosis infection does not disappear. Many times, women are divorced 
because of their tuberculosis infection. Divorce does not occur in all cases when married women 
are diagnosed with tuberculosis but additional tensions that isolate the patient from the 
household are present. Often, infected women are forbidden from sharing food and utensils with 
other family members. Additionally, they will be relegated to their own sleeping spaces instead 
of sleeping beside their husband (Somma et al., 2008).  
Women in Malawi and India are not the only ones suffering isolation from their families 
in relation to contracting tuberculosis. Tuberculosis as a metaphor for isolation is relevant to 
women living in rural Bangladesh as well. Becoming isolated from their families by being 
unable to fulfill their duties as wives and mothers is specifically a concern in this geographic 
location (Karim et al., 2011). In rural Bangladesh, it is frowned upon if women need assistance 
completing their housework. However, when suffering from tuberculosis, the body becomes 
increasingly weak and physically wastes away. Therefore, many women suffering from the 
disease need help doing their daily work. These women are heavily stigmatized and the results of 
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this stigmatization can be disastrous. In some cases, women are sent away from their husbands 
and children and back to their original homes to live with their biological families (Somma et al., 
2008).  Although this brings them closer to their original families, being forced to leave their 
husband and possibly children further isolates them and reinforces the idea that tuberculosis can 
serve as a metaphor for isolation. 
Additionally, as identified by D. Somma et al., suffering from active tuberculosis can 
mean serious physical consequences to women living in this geographic region as well (p. 861). 
Unlike women in India and Malawi reported to the researchers, wives in Bangladesh reported 
suffering brutal assaults from their husbands after being diagnosed with tuberculosis. D. Somma 
et al. (2008) assert, “Many Bangladeshi women also reported that their husbands had physically 
or verbally assaulted them, or refused to bear any expenses associated with treatment” (p. 861). 
Being physically beaten by their husbands does not make wives feel more included in their 
families. On the contrary, it is likely that these verbal and physical abuses further a woman’s 
feeling of isolation from her family, specifically from her husband. 
Unfortunately, because women’s mobility is limited and they are financially dependent 
on their husbands once they marry, contracting tuberculosis can tragically affect a woman’s life. 
Feeling isolated from her family causes significant insecurity regarding the woman’s marriage 
and whether she will be provided for. Therefore, many women hide their symptoms or diagnosis 
from their families and might not even seek medical attention to treat their infection. Receiving 
this assistance would mean public disgrace and ridicule (Somma et al., 2008). By not seeking 
medical attention, women with active tuberculosis are capable of spreading the disease to other 
members of their family or the community as a whole.  
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Overall, as the examples from India, Malawi, and Bangladesh all illustrate, women 
around the world feel significantly stigmatized and isolated from their families due to active 
tuberculosis infections. Eliminating the stigmas and negative perceptions associated with 
tuberculosis could significantly improve the lives of women all over the world suffering with 
tuberculosis. Without its stigma and metaphor for isolation, tuberculosis infections infecting 
women would no longer incur feelings of insecurity. Maybe, if tuberculosis was no longer a 
metaphor for isolation, women would seek treatment promptly and fewer would suffer and die 
from tuberculosis. Ideally, this would translate into fewer women transmitting the disease to their 
family members and eventually less of these family members transmitting tuberculosis to other 
members of the community that they come in contact with.  
 
ISOLATION FROM SELF 
 Characterizing the way a tuberculosis patient suffers from self-isolation is more difficult 
than characterizing the previous two ways that tuberculosis functions as a metaphor for isolation 
in the individuals that suffer from it. The information supporting the presence of self-isolation in 
tuberculosis patients relies on the honest testimonies of individuals suffering from the disease, 
which can some times be difficult to procure. Despite these difficulties, the concept of 
tuberculosis patients undergoing self or mental isolation is a major component of the hidden 
burden of tuberculosis. This personal form of isolation is present in tuberculosis patients across 
the world and has been plaguing patients for decades. 
Although my oma was unable to definitively say whether or not my great-oma suffered 
through this type of mental turmoil, it is difficult to imagine that being stripped away from your 
family and living in a sanatorium would not result the manifestation of a personal form of 
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isolation or that a patient would remain unscathed. Suzanne Bitner was admitted to a sanatorium 
not long after he Bitner’s arrival at the refugee camp in Linz, Austria, and never lived with her 
family again after that. Even after being able to leave the sanatorium, she knew that she still 
needed to isolate herself from the rest of the family and lived in a storage room on a farmer’s 
property for the remaining months of her life. It seems logical to assume that self-isolation could 
easily affect a person living in these circumstances. 
 Unfortunately, self-isolation is something that patients suffering from tuberculosis still 
suffer from today. Men with active tuberculosis infections in Chennai, India undergo self-
isolation and retraction from society due to their disease (Somma et al., 2008). One man said, 
“When I cough loudly, especially in front of others, I feel so embarrassed and feel a nuisance. I 
therefore stay away from work or other social groups” (as cited in Somma et al., 2008). It is 
difficult enough to be suffering from the disease itself, but patients themselves stigmatize the 
disease and isolate themselves from society because of it (Somma et al., 2008).  
Self-isolation suffered by tuberculosis patients is no different in Chicago, Illinois. Patricia 
Kelley published an article entitled “Isolation and Stigma: The Experience of Patients with 
Active Tuberculosis” in 1999 that identified and analyzed some of the perceptions of 
tuberculosis that patients and surrounding community members have about the disease. She 
interviewed patients in Lawndale and Englewood, two low-income neighborhoods in Chicago, 
and her data identified that he way the disease is transmitted, allowing stigma to define 
themselves, and being secretive about their disease were all ways that tuberculosis patients coped 
with their disease (Kelley, 1999). These factors all resulted in or facilitated a patient’s self-
isolation. 
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One self-isolating factor that was noticed in tuberculosis patients was that the patients 
identified themselves as vectors. They knew that they could spread the disease to others, which 
caused the patients a significant amount of fear that they would spread the disease to their family 
members or others that they came in contact with. Kelley quoted one patient saying, “It is very 
important to me to know if I can give the disease to others. That’s why I don’t want to be around 
other people” (as cited in Kelley, 1999). Other patients left their homes or were sent away by 
their families because of their potential for spreading the disease to others in their households. 
Once again, this identifies the patient as a vector and elicits feelings of isolation in patients 
suffering from tuberculosis (Kelley, 1999). Therefore, a patient identifying himself or herself as 
a vector supports their self-isolation. 
Additionally, feeling stigmatized can also lead patients to suffer from self-isolation. 
Patients identified that being stigmatized was one of the major problems that being infected with 
tuberculosis has caused them. One patient even said that they were a menace now that they were 
infected with tuberculosis. Patients suffer from self-isolation by allowing the stigma and 
perception of tuberculosis to dominate their self-image (Kelley, 1999). In turn, this results in 
patients isolating themselves. 
The final factor that played a role in causing patients with tuberculosis to suffer from 
self-isolation is that patients with active tuberculosis infections often kept their disease a secret. 
Many patients avoid telling people that they were diagnosed. Interviewed patients mentioned that 
they would tell people that they had a lung problem instead of telling people that they have 
tuberculosis. These patients mentioned that people react negatively to an individual when they 
learn that a person has been diagnosed with tuberculosis. According to these patients, even the 
word tuberculosis is bad. Therefore, to avoid being stigmatized by others after telling them about 
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their diagnosis, tuberculosis patients withdraw into secrecy and isolate themselves (Kelley, 
1999).  
Self-isolation by tuberculosis patients is not unique to the low-income neighborhoods that 
Patricia Kelley studied in Chicago. Dodor et al. (2008) recognized that tuberculosis patients 
living in the Shama Ahanta East Metropolitan District of Ghana also suffered from self-isolation 
(p. 1051). These researchers noticed that secrecy, just like in Chicago, was one of the driving 
factors behind tuberculosis patients stigmatizing themselves. Patients in this district of Ghana hid 
their diagnosis from their family and friends. In order to effectively hide their diagnosis, 
tuberculosis patients would avoid interacting with their communities and being in public in 
general. The patients were afraid of being devalued by society if their peers were to learn about 
their diagnosis, so they stigmatized themselves and forced themselves into self-isolation (Dodor 
et al., 2008).  
In Chicago and Ghana’s Shama Ahanta East Metropolitan District, one of the driving 
forces that causes tuberculosis patients to suffer from self-isolation is fear. Fear presents itself in 
different ways in the patients interviewed at these two sites. The patients interviewed in Chicago 
were afraid of their disease as well as how they were perceived in the community. Patients were 
scared that they would spread the disease to their loves ones, and were afraid that they would be 
rejected and stigmatized by their community (Kelley, 1999). In Ghana, the patients were also 
afraid of being shunned by their community (Dodor et al., 2998). All of the cases that both of the 
studies recognize, show that fear plays a major role in causing patients to isolate themselves once 
they are infected with tuberculosis. 
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Conclusion            
 Tuberculosis has plagued humans for centuries. Beginning in ancient human civilizations 
in Africa, tuberculosis infections continue to persist despite incredible advances in antibiotic 
formulation, development of programs designed to address tuberculosis specifically, and 
numerous other intervention strategies. Considering that the inhabitants of twenty-two countries 
in the world are still considered to suffer from high burdens of the disease, the battle against 
tuberculosis needs to continue. It continues to be a disease that kills numerous people every year 
despite being both curable and preventative.  
 Because it is treatable and preventable, one should be dying from tuberculosis anymore. 
Keeping this in mind, it becomes necessary to answer the questions: why do people still suffer 
from tuberculosis and how can it be stopped? As seen throughout this thesis, there are many 
different intervention methods, ranging from specific medications to programs determining the 
support systems available for patients suffering from tuberculosis, used to treat tuberculosis that 
contribute to why people still suffer from the disease today. Combining these intervention 
methods with perceptions of tuberculosis that make it a metaphor for isolation results in many 
ineffective and inefficient treatment methods.  
 For example, an instance in which a potentially beneficial treatment method could 
become ineffective due to perceptions surrounding tuberculosis is Directly Observed Therapy 
(DOT). The CDC recommends that a family member should not be the observer overseeing the 
patient taking their medication while enrolled in a DOT program. According to the CDC, if an 
observer is a family member they might be slightly more lenient with the patient (CDC, 2012c). 
However, studies have shown that one family member providing DOT for another family 
member is not always less effective than having someone else providing the therapy (Kabongo & 
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Mash, 2010). Therefore, having a family member provide DOT might be a more convenient 
solution for a patient receiving anti-tuberculosis drugs. However, when deciding who should 
oversee a patient taking their medication in a DOT program, the perceptions surrounding 
tuberculosis need to be considered. As previously mentioned, patients with active tuberculosis 
infections sometimes feel isolated from their families. This is especially applicable to women 
who feel estranged from their families, particularly their husbands, after being diagnosed. 
Therefore, having a family member provide DOT might not be most effective in this case. The 
overlap between treatment efficacy and perceptions associated with tuberculosis highlights the 
importance of evaluating what tuberculosis treatment methods will be most effective in a way 
that is both culturally relevant and case sensitive 
 Another example of the interplay between perceptions of tuberculosis and treatment 
methods used to combat the disease is the connection between patients not seeking medical 
attention and the isolation that patients with tuberculosis feel from their communities. As was 
previously mentioned, in some areas of the world, individuals are afraid to go to medical clinics 
when feeling ill because they are afraid of being diagnosed with tuberculosis. The diagnosis does 
not only incur physical discomfort due to the disease but also emotional discomfort because of 
the community’s reaction to it. Often being diagnosed with tuberculosis causes patients to lose 
their jobs and be publically ridiculed. Therefore, regardless of how sensitive and advanced the 
machinery or health care workers are that can diagnose a patient with tuberculosis, the patients 
will not be seen if they do not seek medical attention. Once again, if the perceptions surrounding 
the disease were debunked, perhaps more patients would seek medical attention. The more 
patients that seek medical attention, the fewer contagious patients there will be thus hopefully 
decreasing transmission of the disease. 
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 Although these connections between treatment methods and perceptions of tuberculosis 
are important to highlight, simply being aware of them does not eradicate tuberculosis. To 
decrease the incidence and prevalence rates of tuberculosis, attempting to eliminate the 
perceptions surrounding the disease could be a good place to start. One way to eliminate these 
perceptions is through educating communities about the way tuberculosis spreads and how long 
individuals are contagious for after beginning their medication. It is not my intention to sound 
paternalistic, and I realize that education does not solve all of the issues associated with 
tuberculosis. However, it could be a good place to start because many perceptions that result in 
tuberculosis being a metaphor for isolation are rooted in misconceptions about the disease. For 
example, even after a man living in Bangladesh is cured of tuberculosis, he is unable to come 
back to work. Perhaps if employers were reminded that after being treated patients are no longer 
contagious, individuals with active tuberculosis infections would feel less isolated from their 
communities because they could return to work after receiving treatment. In turn, this could then 
provide incentive for patients to seek medical attention when they suffer from symptoms 
associated with tuberculosis.  
 In addition to education, one of the most important areas of improvement that could 
reduce the incidence and prevalence rates of tuberculosis around the world is increasing the 
amount of contact tracing. Contact tracing is important because it allows healthcare facilities and 
workers to determine who might have been exposed to M. tuberculosis due to coming in contact 
with an individual suffering from an active tuberculosis infection. Once an individual is exposed 
to the bacteria, they are at risk for developing the disease themselves, becoming contagious, and 
spreading it to others. Although issues arise with indexing contact cases and deciding what 
should be done to clinically analyze an individual after they are identified as a contact, this 
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process could be extremely important in preventing the disease from infecting many more 
individuals (WHO, 2012a). By implementing effective contact tracing procedures, public health 
practitioners and healthcare workers can focus on preventing tuberculosis. Ideally, prevention 
methods would be so effective that tuberculosis incidence rates would decrease because no one is 
contracting it any more.  
 In conclusion, I recognize that this thesis only scratches the surface of tuberculosis’s 
devastatingly far-reaching effects. Other factors related to tuberculosis that require further 
consideration are tuberculosis’s effects on patients living in regions of conflict, who the best 
person to administer DOT is and what this means for tuberculosis treatment, and how drug 
toxicity can be regulated to effectively treat TB/HIV co-infections and multidrug-resistant cases 
of tuberculosis. Overall, there is not one way to treat tuberculosis that will be effective in all 
cultural contexts and for every individual case. Culturally sensitive and case specific treatment 
methods will most likely be the best way to battle this tragic disease. Combining individualistic 
treatment methods with debunking current perceptions of the disease will allow the medical field 
and communities all over the world to make significant strides in decreasing prevalence and 
incidence rates.  
Although much needs to be done to eradicate tuberculosis, it is a necessary and 
worthwhile goal that the global community should strive for. Striving to rid the world of this 
disease will mean that less people will suffer the way my oma did upon losing her mother to 
tuberculosis. Seeing the sadness in my oma’s eyes as she tells her mother’s story still breaks my 
heart but behind the sadness exists a gentle strength. My oma was strong through her mother’s 
death and has been strong through countless difficult times throughout her life since then. While 
sitting next to her after our long discussion about her life and my great-oma’s illness, she pulls 
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out a book entitled “Illyatscha,” of which she is one of the co-authors. The Donauschwaben are 
proud of their heritage, and my oma continues to carry this pride with her every day of her life. 
She lived in a refugee camp for most of her early life, her mother died of tuberculosis, and she 
lost almost everything she owned. Many people would crumble at the weight of these difficult 
circumstances, but my oma did not. Instead, she chose to survive and now I have the pleasure of 
spending time with her. Talking about her mother was an emotional discussion, but our 
conversation slowly drifted into admiring the beauty of nature surrounding us on the porch of 
their condominium. My oma is an amazing woman, and I am proud to be her granddaughter. I 
am proud to be a Donauschwaben, and I will carry this pride with me throughout my life. 
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